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MYOCARDIAL T1 MAPPING TECHNIQUES FOR
QUANTIFICATION OF MYOCARDIAL FIBROSIS

XIAOPENG ZHOU

ABSTRACT
Identifying and quantifying diffuse myocardial fibrosis is important to provide
insights into the relationship between myocardial fibrosis, diastolic and systolic
dysfunction, as well as clinical outcomes. T1 mapping is a promising technique for
noninvasively identifying diffuse myocardial fibrosis in heart failure. A quantitative T1
map provides sensitivity to the full range of T1 values and is advantageous over the
traditional T1-weighted imaging by reducing the reliance on visual interpretation of the
signal intensity in the myocardium. However, in-vivo myocardial T1 quantification is
challenging because of cardiac and respiratory motion. During the past few years, a
variety of T1 mapping techniques, including the modified Look Locker inversion
recovery (MOLLI) sequence, have been developed and optimized to measure the
myocardial T1 value. Importantly, there have been significant differences between the T1
values determined by various methods, and several aspects of T1 mapping are
incompletely understood. The accuracy of T1 mapping is sensitive to several
confounding factors, such as the types of T1 mapping acquisition sequence and
individual physiologic parameters. It also remains unclear if myocardial T1 values are
vi

constant throughout the cardiac cycle or the cyclic variation from the error of the variable
flip angle (VFA) technique. Lastly, it is necessary to validate these techniques against the
endomyocardial biopsy.
The work intends to validate several aspects of T1 mapping. Firstly, whether there
is significant cyclic variation of myocardial T1 at 1.5T was assessed in healthy volunteers
and patients without myocardial disease. Secondly, a fast 3D DFA technique with B1
correction was developed to measure T1 comparably with gold standard in a wide range
of T1 values, which showed it is necessary to incorporate B1 correction at 3T. Thirdly,
Look Locker and MOLLI were compared to evaluate their agreement and difference in 3
patient groups precontrast and postcontrast situations. Finally, the T1 mapping technique
was applied in a group of patients with diffuse myocardial fibrosis eligible for myectomy
surgery. Precontrast and postcontrast myocardial T1 values were assessed to identify and
quantify myocardial fibrosis, with subsequent histological validation based on intraoperative biopsies. The extracelluar volume calculated from T1 values positively
correlated with histological analysis, which can help to guide the decision-making
regarding when to send patients for invasive surgery and follow changes of fibrosis in the
myocardium over time with noninvasive assessment.
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CHAPTER I
INTRODUCTION

Cardiovascular disease (CVD) is the disease of the heart and circulatory system.
CVD is the leading threat to human health in the United States and the Western World. It
is estimated by the American Heart Association that 80 million people in the United
States have one or more forms of CVD. With the growing epidemic of obesity, diabetes,
and hypertension, in addition to longer life expectancy, 40.5% of the US population is
projected to have some form of CVD by 2030 [1].
CVD encompasses a number of specific illnesses such as coronary heart disease,
heart failure (HF), cardiomyopathies, arrhythmias, stroke, arterial and pulmonary
hypertension, congenital heart disease, valvular heart disease, etc [2]. Among all the
forms of CVD, HF is associated with significant morbidity, mortality, and financial
burden to health care services, causing over 1,000,000 hospitalizations /year in the United
States [3]. HF represents a complex physiologic state characterized by a reduced cardiac
output that can not meet systemic demands. The major challenges in HF management are
to identify the underlying etiology and make early diagnosis [4]. Although significant
advances occurred in the last 20 years to manage the systolic HF, many patients progress
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to end-stage cardiomyopathies [3]. It is of particular importance to accurately and
noninvasively determine the cardiac function for diagnosis and treatment of the heart
diseases. Magnetic resonance imaging (MRI) is a rapidly evolving modality, providing
noninvasive assessment of cardiac morphology, function, perfusion and tissue
characterization for patients [2, 4]. A stepwise approach using cardiovascular MRI was
proposed to evaluate and manage of patients who have HF and specific cardiomyopathis
[2],

which

includes

assessing

morphology

and

function,

characterizing

the

cardiomyopathy and risk stratification and therapeutic management. However,
development of the means to acquire and analyze these images is still an evolving and
promising area to explore clinical application.

1.1 Background

The term “cardiomyopathy” was defined as non-coronary myocardial disease by
Wallace Brigden for the first time in 1957 [5]. The definition of cardiomyopathies has
been evolving and updating with the development of diagnostic technology.
In 1995, World Health Organization (WHO) /International Society and Federation
of Cardiology (ISFC) Task Force defined cardiomyopathies as “diseases of myocardium
associated with cardiac dysfunction” [6]. The cardiomyopathies were classified according
to anatomy and physiology into the following types: dilated cardiomyopathy (DCM),
hypertrophic

cardiomyopathy

(HCM),

restrictive

cardiomyopathy

(RCM),

arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), and unclassified
2

cardiomyopathies. This version of definition and classification is more widely used in the
years afterwards. However, classifying for heart muscle disease is exceedingly complex.
With better understanding of etiology and pathogenesis, dramatic advances in diagnosis
and rapid evolution of molecular genetics in cardiology, a new contemporary definition
and classification of cardiomyopathies was proposed by the American Heart Association
(AHA) in 2006 [7] in concert with the molecular era of cardiovascular disease. The AHA
expert consensus panel defined that “Cardiomyopathies are a heterogeneous group of
diseases of the myocardium associated with mechanical and/or electrical dysfunction that
usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilatation
and are due to a variety of causes that frequently are genetic. Cardiomyopathies either are
confined to the heart or are part of generalized systemic disorders, often leading to
cardiovascular death or progressive heart failure–related disability.” Cardiomyopathies
are classified into two groups: primary cardiomyopathies (predominantly involving the
heart) and secondary cardiomyopathies (accompanied by other organ system
involvement).
Determining the exact etiology is essential for directing the correct treatment and
predicting survival. Cardiovascular MRI (CMR) is a rapidly evolving technology that is
increasingly being used for the noninvasive imaging of the expanding HF population [8].
CMR has the potential to characterizing the myocardial and valvular structures and
function, differentiating ischemic versus nonischemic cardiomyopathy, evaluating the
risk stratification for therapeutic management [2].
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1.2 Evaluation of Cardiomyopathies Using MRI

In comparison to other imaging modalities, including ultrasound, X-ray
fluoroscopy and computed tomography (CT), MRI provides excellent spatial resolution
and soft tissue contrast without radiation exposure. One of the most intriguing features of
MRI is that it can provide various tissue contrasts by adjusting the parameters of the
pulse sequence, such as flip angle, echo time and repetition time. For a typical MRI scan,
the image contrast is predominately determined by spatially varying proton density, spinlattice (or T1) relaxation time, and spin-spin (or T2) relaxation time. By using different
pulse sequences and acquisition parameters, MRI allows us to examine myocardial
function, morphology, perfusion, valvular function, myocardial tissue characterization
and so on. Given its enhanced spatial resolution, improved tissue characterization, and
lack of ionizing radiation, MRI has become the best of choice in the evaluation of
patients with new-onset cardiomyopathy of unknown etiology.
The application of gadolinium based extracellular contrast agents can further
extend the ability of MRI to discriminate ischemic from nonischemic etiologies due to
different hyperenhancement patterns among the various nonischemic cardiomyopathies.
Delayed enhancement (DE) MRI delineates areas of myocardial fibrosis, by imaging 10–
15 minutes after gadolinium contrast administration. Delayed gadolinium retention in the
interstitial space is increased in conditions with increased extracellular volume of
distribution and/or decreased washout such as acute necrosis, fibrosis, infiltration and
inflammation [9]. Since gadolinium shortens T1 relaxation time, it results in brighter
signal intensity in the areas with increased interstitial space on inversion recovery T14

weighted sequences [10-13]. This technique is sensitive and reproducible in the detection
of myocardial scar. In an international, multicenter trial, DE MRI was associated with a
sensitivity of 94–99% to detect myocardial infarction. Likewise, the accuracy of MRI for
identifying myocardial infarction location (compared with infarct-related artery perfusion
territory) was 99% (acute) and 91% (chronic) after contrast compared with 9% before
contrast [14]. It is also important to note that the presence of DE is not specific for any
cardiomyopathy. It is the location and pattern of DE that helps the final diagnosis and
distinguishes the various etiologies of cardiomyopathies [15]. Multiple MRI sequences
are often used in the assessment of cardiomyopathy. The combination of cine function,
myocardial perfusion at rest and stress, and DE MRI helps the clinician elucidate the
cause of the cardiomyopathy. It provides accurate and reproducible volumetric
assessment of the left and right ventricular sizes, volumes, wall thicknesses and mass in
addition to the ejection fraction with small inter- and intra-observer variability [1, 15].

1.2.1 Ischemic Cardiomyopathy

Although the 2006 AHA expert consensus panel did not support the term
“ischemic cardiomyopathy”, the classification of cardiomyopathies as ischemic and nonischemic cardiomyopathy is still widely used. ICM is defined as dysfunction of the left
ventricle as a result of a chronic lack of oxygen due to coronary artery disease [16].
About 1 out of 100 adults over the age of 60 have ICM. The prevalence of ICM in
western countries is increasing despite improvements in prevention, diagnosis, and
treatment of cardiovascular disease.
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In the setting of coronary artery disease, myocardial ischemia may result in
stunning, hibernation, and true infarction. Stunned myocardium occurs following an
acute ischemic insult resulting in reversible contractile dysfunction. Hibernation
describes chronic contractile impairment secondary to chronic hypoperfusion, where the
myocardium is still viable. By either percutaneous coronary intervention or coronary
artery bypass grafting, viable tissue can be revascularized and therefore myocardial
contractility of the viable tissue can be improved. In contrast, patients with full thickness
infarcted (scarred) tissue will not benefit from revascularization [17].
On delayed contrast enhanced T1-weighted images, infarcted tissues appear
bright with decreased segmental contractile ability apparent on the corresponding cine
images. On DE MR images, infarcted myocardium and fibrosis appear as high signal
intensity in an area of coronary artery distribution. Since all infarctions start
subendocardially and may progress towards epicardium, the subendocardium is always
involved.

Figure 1-1: Short axis delayed enhancement images of a patient with ICM
6

DE MRI can be used following an ischemic event to help to distinguish between
myocardial infarction (characterized by delayed contrast enhancement and segmental
contractile dysfunction), viable but ischemic myocardium (characterized by segmental
contractile dysfunction without delayed contrast enhancement) and normal myocardium.
The extent of myocardial delayed hyperenhancement postmyocardial infarction
has important prognostic implications. It is generally accepted that the extent of
transmural hyperenhancement within a myocardial segment is inversely proportional to
the degree of expected functional recovery. Extensive involvement is highly predictive of
a lack of functional improvement following revascularization [17]. Conversely, absence
of delayed hyperenhancement within a segment of poor contractility correlates with a
high likelihood of functional recovery after revascularization [11, 18].

1.2.2 Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease
characterized morphologically by abnormal hypertrophied, in the absence of dilatation of
the LV wall, which is usually asymmetric most prominently involving the interventricular
septum with normal or reduced LV volume. Compared with normal ventricular septal
measurement is 8-12 mm, the diastolic left ventricular wall thickness is 15mm or more
[16]. The interventricular septum is typically more prominently involved than the left
ventricular free wall, but concentric and apical hypertrophy can occur.

The left

ventricular volume is normal or reduced in HCM, and diastolic dysfunction is usually
present. Arrhythmias and premature sudden death are common in HCM. Characteristic
7

histologic changes include myocyte hypertrophy and disarray, which usually corresponds
to the areas of greatest hypertrophy [14, 15].
HCM is a genetic myocardial disorder with a prevalence of 1:500 [16] and
probably the most frequently occurring cardiomyopathy. HCM is caused by a variety of
mutations in genes encoding contractile proteins of the cardiac sarcomere. Currently, 11
mutant genes are associated with HCM, most commonly β-myosin heavy chain (the first
identified) and myosin-binding protein C [7].
Typically, HCM patients display patchy, multifocal hyperenhancement occurring
only within hypertrophied regions (Figure 1-2). The junction of the right ventricular free
wall with the interventricular septum is frequently affected [17, 19, 20]. It is thought that
the patchy enhancement is due to the presence of abundant connective tissue within the
hypertrophic myocardium [21]. It has been proposed that the extent of delayed
hyperenhancement may have prognostic implications, with the more severe
manifestations of the disease, such as end-stage heart failure and sudden death, occurring
more frequently in patients with high levels of delayed hyperenhancement reflecting high
levels of myocardial fibrosis [20, 22]. However, diffuse myocardial fibrosis in HCM
patients cannot be detected by DE MRI because the image contrast on DE MR images is
on the basis of the difference in signal intensity between fibrotic and “normal”
myocardium and such differences may not exist if the myocardial fibrosis is diffusive.
Thus, the diffusive fibrosis will be nulled and not show hyperenhancement. The
myocardium is thickened, and delayed enhancement is patchy.
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Figure 1-2: Short axis delayed enhancement images of a patient with HCM

1.2.3 Dilated Cardiomyopathy

Dilated cardiomyopathy (DCM) is characterized by ventricular chamber
enlargement with an end diastolic diameter greater than 55 mm and impaired function of
the left ventricle with an ejection fraction smaller than 45% or both ventricles [16]. The
complete list of causes of DCM is extensive. It may be idiopathic, familial/genetic, viral
and/or immune, alcoholic/toxic, or associated with recognized cardiovascular disease in
which the degree of myocardial dysfunction is not explained by the abnormal loading
conditions or the extent of ischemic damage [6]. DCM leads to progressive heart failure
and a decline in LV contractile function, arrhythmias, conduction system abnormalities,
and sudden death. Indeed, DCM is a common and largely irreversible form of heart
muscle disease with an estimated prevalence of 1:2500 [7].
9

Patients with idiopathic dilated cardiomyopathy show either no enhancement or
linear midmyocardial enhancement [13, 16]. This enhancement is explained by the
presence of fibrosis. Patients with midmyocardial enhancement are at higher risk of
sudden cardiac death and arrhythmias [23]. The differentiation between idiopathic dilated
cardiomyopathy and ischemic dilated cardiomyopathy is important, as ischemic
cardiomyopathy might be treated with revascularization and idiopathic disease might not.
Late enhancement MRI will show subendocardial enhancement in patients with ischemic
cardiomyopathy. Figure 1-3 shows that DCM with septal mid-wall fibrosis (left) and
DCM without delayed enhancement (right) [24].

Figure 1-3: Short axis delayed enhancement images of a patient with DCM

1.2.4 Restrictive Cardiomyopathy

Restrictive cardiomyopathy is characterized by impaired ventricular filling and
reduced diastolic volume of either or both ventricles with normal or near-normal systolic
10

function and wall thickness [6]. Hypertrophy is typically absent, although infiltrative
disease (such as amyloidosis) and storage disease (such as Fabry disease) may cause an
increase in left ventricular wall thickness. Systolic function usually remains normal, at
least early in the disease. Increased interstitial fibrosis may be present. The most common
cause of restrictive cardiomyopathy is amyloidosis. Amyloid deposits in the myocardium
cause abnormal diastolic function with biatrial enlargement, concentric thickening of the
left ventricle and reduced systolic function of usually both ventricles. Cardiac
involvement in systemic amyloidosis occurs in up to 50% and has a poor prognosis with
a median survival of 6 months [2, 16]. Restrictive cardiomyopathy is much less common
than either dilated or hypertrophic cardiomyopathy. Symmetrical left ventricular
hypertrophy with the classical ‘zebra’ pattern of DE is seen [25] on Figure 1-4.

Figure 1-4: Short axis delayed enhancement images of a patient with amyloidosis
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1.3 Detection and Quantification of Myocardial Fibrosis in Cardiomyopathies

Myocardial fibrosis, defined by a significant increase in the collagen volume
fraction of myocardial tissue, is one of the most common histological features of the
failing heart. It is caused by extracellular matrix (ECM) remodeling, which leads to
increased myocardial stiffness, impaired cardiac diastolic and systolic function.
Myocardial fibrosis is found in focal patterns following coronary territories in ischemic
scar, but also as more diffuse myocardial fibrosis occurring in a variety of non-ischemic
cardiomyopathies [26, 27].

1.3.1 Pathogenesis of Myocardial Fibrosis

Myocardial fibrosis is part of myocardial remodeling, which can be secondary to
a wide range of pathologic conditions, including ischemia, pressure or volume overload,
viral infection, or genetically mediated injury as in hypertrophic cardiomyopathy. Net
collagen deposition is caused by an imbalance of its synthesis relative to degradation.
Myocardial remodeling and fibrosis are associated with an imbalance between syntheses
relative to degradation of the myocardial ECM. Several enzymes have been identified as
potential mediators of myocardial ECM turnover. Among several groups of enzymes that
mediate myocardial ECM turnover, the matrix metalloproteinases (MMPs) have a
prominent role. The matrix metalloproteinases (MMPs) are endopeptidases, which have
different substrates: MMP-1 and -13 are collagenases and MMP-2 and -9 gelatinases. The
activity of the MMPs is regulated by a group of tissue inhibitors of matrix
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metalloproteinase (TIMPs). The complex balance between MMPs and TIMPs, which
determines ECM turnover and fibrosis, is only partially understood [28].
The distribution and characteristics of myocardial fibrosis varies according to the
underlying pathology. There are three types of myocardial fibrosis: infiltrative interstitial
fibrosis, interstitial reactive fibrosis and replacement fibrosis [26]. Infiltrative interstitial
fibrosis is induced by the progressive deposit of insoluble proteins (amyloidosis) or
glycosphingolipids (Anderson-Fabry disease) in the cardiac interstitium. Interstitial
reactive fibrosis often distributes diffusively within the interstitium, but it can also be
confined to the perivascular region. This type of fibrosis has a progressive onset and
follows the increased collagen synthesis by myofibroblasts responding to different
stimuli. It has mostly been described in hypertension and diabetes mellitus. It is also
present in the aging heart, in idiopathic dilated cardiomyopathy, in left ventricular (LV)
pressure-overload and volume-overload states induced by chronic aortic valve
regurgitation and stenosis, and in the remote noninfarcted myocardium after infarction.
Interstitial fibrosis is reversible under specific therapy and is the target for treatment.
Therefore, there is clinical interest in its assessment for the management of patients with
hypertension, diabetes, primary dilated cardiomyopathy, and valvular disease. Interstitial
fibrosis and infiltrative fibrosis can develop further into replacement fibrosis in the later
stages of disease. Under this condition, cellular damage and cardiomyocyte
necrosis/apoptosis appear. This replacement fibrosis emerges once the myocyte integrity
is damages, mainly consisting of type I collagen [26].

1.3.2 Endomyocardial Biopsies
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Myocardial biopsy is the standard method to quantify diffuse fibrosis. This
methodology enables qualitative macroscopic assessment after Masson Trichrome
staining and quantitative absolute assessment of the collagen volume fraction in tissue
samples by quantitative morphometry with picrosirius red, which specifically stains
fibrillar collagen under polarized light. It allows absolute quantification of fibrosis in
myocardial samples. However, this invasive technique is associated with a risk of
significant morbidity and is prone to sampling error [29, 30]. Furthermore, fibrotic
involvement of the whole LV cannot be determined [26, 29]. Development of a technique
which can noninvasively quantify the diffusive myocardial fibrosis is highly critical and
desirable, not just in terms of disease stratification but also in evaluating newer therapies
aimed at reducing myocardial fibrosis in the treatment of heart failure.

1.3.3 Detection of Myocardial Fibrosis by DE MRI

DE MRI is a widely used and well-established powerful clinical technique used to
evaluate ischemic and non-ischemic disease of the myocardium. Typically, a
paramagnetic contrast agent (0.1–0.2 mmol/kg) is injected into a patient to temporarily
distribute in the extravascular, extracellular, space (ve) in the myocardium [31]. Under
the condition of replacement myocardial fibrosis, the myocytes have been replaced by
collagen fiber and the loss of viable cardiac cells results in an increased ve where the
contrast agent can accumulate in infarcted regions. The increased gadolinium
concentration shortens the myocardial T1 value, making higher signal intensity in scar
tissue visible when an inversion recovery sequence is set to null the normal myocardium.
DE MRI was initially developed for characterization of myocardial damage after
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myocardial infarction [32-35]. This technique has become the gold standard for
noninvasive identification and quantification of myocardial scar tissue or replacement
fibrosis. On delayed enhancement MR images, ischemic scar appears bright in a
subendocardial or transmural pattern following the vascular distribution of the major
coronary arteries. In nonischemic myocardial disease, the delayed enhancement usually
shows non-vascular patterns and distributes diffusively, in a midwall distribution [35].
However, it is limited in its accuracy for absolute quantification of myocardial
fibrosis, and the assessment of diffuse fibrosis is restricted by technical and
physiopathological characteristics [26, 29]. First, with conventional DE MRI sequences,
signal intensity is expressed on an arbitrary scale that differs between scans and thus, is
unsuitable for direct signal quantification in cross-sectional or longitudinal comparisons.
Second, image contrast is on the basis of the difference in signal intensity between
fibrotic and “normal” myocardium, and such differences may not exist if the myocardial
fibrosis is diffusive. Although a diffusely fibrotic myocardium would accumulate contrast
agent in a similar way as in scarred myocardium, “normal” myocardium with diffuse
fibrosis is “nulled” to highlight focal scar. Thus, diffuse myocardial fibrosis cannot be
detected by DE MRI. As signal intensity of each single voxel is a mixture which cannot
represent the difference between normal and abnormal myocardium. Collagen often
diffusively deposits in non-ischemic cardiomyopathy. Such interstitial fibrosis commonly
shows no regional scarring on delayed contrast enhancement images and is often missed
by DE MRI.
Unlike fixed scar, diffuse myocardial fibrosis may be reversible and is a treatment
target [29, 36]. Although regional fibrosis is easily imaged with CMRI there is no
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noninvasive method for quantifying diffuse myocardial fibrosis. Currently, invasive
biopsy is the only method to quantify diffuse fibrosis, which may cause significant
morbidity and is prone to sampling error [29, 30]. Development of a technique which can
noninvasively quantify the diffusive myocardial fibrosis is highly critical and desirable to
stratify disease and evaluate newer therapies for the treatment of heart failure.

1.3.4 Potential of Myocardial T1 Mapping to Differentiate Myocardial Fibrosis

Diffuse myocardial fibrosis is a fundamental process in pathologic remodeling in
cardiomyopathy and is postulated to cause increased cardiac stiffness and poor clinical
outcomes. Evaluation of the presence and degree of myocardial interstitial fibrosis are
important for diagnosis, treatment and prognosis of cardiac diseases. The degree of
myocardial fibrosis is thought to play a critical role in determining a patient’s risk for
sudden cardiac death. However, DE MRI has limited ability to detect diffuse fibrosis and
endomyocardial biopsy is invasive and prone to sampling error. Several attempts with T1
mapping techniques have been made to quantify the degree of myocardial fibrosis
noninvasively [3, 29, 37].
Myocardial longitudinal relaxation time (T1) mapping is an emerging technique
that could improve diagnostic accuracy of CMRI. Cardiac T1 mapping techniques enable
quantification of myocardial signal directly on a standard scale. T1 time shows
significant differences among different tissues and pathologies, and has shown great
potential in characterizing myocardial fibrosis in the context of ischemia/infarction [38,
39] and infiltration (e.g. amyloidosis) [40]. T1 can be utilized to accentuate contrast
16

between normal and pathologic tissue, which is often based on differences in tissue
microstructure. For example, in acute myocardial infarction, ischemic areas present
edema and inflammation which results in a prolonged T1 value in these areas [38]. The
elevation of T1 value could be considerable although the water content may only increase
a few percent in ischemic regions [41]. Therefore T1 may be used to objectively measure
changes in tissue properties and noninvasively characterize tissue as this parameter is
very sensitive to the change of free water content in tissue and can differentiate the
physical property of free water in tissue.
On T1 weighted images of the myocardium acquired for clinical purposes, focal
differences in T1 signal are typically assessed qualitatively by visual inspection. For
more precise, quantitative assessment, T1 times can be determined using multiple scans
with varying T1-weighting. By calculating T1 values on a pixel-by-pixel basis, a
parametric map can be reconstructed, in which pixel intensities correspond to T1 values
[42]. Quantitative T1 maps can provide an absolute scale and may be advantageous over
the traditional T1-weighted imaging, which is assessed using relative units and cannot be
consistently compared between scans or patients [43]. T1 mapping provides sensitivity to
the full range of T1, and could prescribe standardized cutoffs between “normal” and
“affected” myocardium to eliminate inter- and intra-observer inconsistencies in
delineation of the diseased myocardium. T1 mapping therefore is a powerful tool and
holds great promises for characterizing myocardial tissue, with many potential clinical
applications, such as differentiating the gray zone surrounding myocardial scar in
myocardial infarction, quantifying fibrosis in patient with hypertrophic obstructive

17

cardiomyopathy (HOCM), and quantifying the concentrations of contrast agent within the
tissue in dynamic contrast agent studies.
In vivo T1 quantification of the myocardium with modern MR systems is
challenging because of cardiac and respiratory motion. A variety of dedicated cardiac
pulse sequences have been developed for T1 mapping, which can be applied to
characterization of diseased myocardial tissue [39, 42, 44-50]. However, the rapid cyclic
cardiac motion is a significant challenge for image acquisition, validation of these
techniques and comparison between techniques is still limited, requiring further
evaluation of the accuracy of these techniques precontrast and postcontrast agent
injection in various patient groups.

1.4 Physics of T1 Mapping Techniques

1.4.1 Spin-lattice Relaxation Time

1.4.1.1 Bloch Equation
By definition, MRI is a process involving the absorption and emission of energy
by nuclei. For clinical imaging purposes, MRI exploits the magnetic property of
hydrogen protons in human body as a diagnostic tool. The term “spin” is derived from the
quantum mechanical description of MRI. In 1946, Felix Bloch described nuclear MR
phenomenon with a set of equations [51]. Bloch assumed that the ensemble of spins
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could be represented as a net nuclear magnetization (M) behaving according to the laws
of classical electromagnetism. If the spins constituting M interact only with the external
magnetic field (B), they will experience a torque given by the vector cross product
(M×B) [51]. Because the torque of a system is equal to the time rate of change of its
angular momentum, Bloch presented the motion of M could be a simple precession
around B by the equation:
dM / dt = γ [ M × B ]

(1.1)

If the spins interact with each other and their environment, M will not precess
indefinitely around B, but will return to its original alignment with the main magnetic
field (B) with the equilibrium magnitude M0. To return back to the equilibrium state, the
spin system must release its energy to the environment, which was termed as relaxation
by Bloch. Two time constants (T1 and T2) were introduced by Bloch to account for the
reestablishment of the thermal equilibrium of the nuclear magnetization following an RF
pulse. T1 relaxation was assumed following first-order kinetics by Bloch. T1 describes
the recovery of longitudinal magnetization (Mz). By adding the T1 effect to the original
equation (1.1), the modified version of Bloch equation is shown:
dM z / dt = ( M 0 − M z ) / T 1

(1.2)

1.4.1.2 Causes of T1 Relaxation
T1 is also known as spin-lattice relaxation time and describes how fast the
longitudinal magnetization recovers to its equilibrium. Regrowth of longitudinal
relaxation requires a net transfer of energy from the nuclear spin system to its
environment (“lattice”) [51]. Because T1 relaxation requires an energy exchange, and
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because all MR energy exchanges must be stimulated, T1 relaxation only can occur when
a proton encounters another magnetic field fluctuating near the Larmor frequency. The
source of this fluctuating field is typically another proton or electron, and the interaction
is called a dipole-dipole interaction.
In order for a proton or electron to produce a fluctuating magnetic field to cause
the T1 relaxation, the molecule in which it resides must be tumbling. The molecule must
be rotating near the Larmor frequency to cause T1 relaxation efficiently. Thus, the
tumbling rate of the molecule can affect the T1 relaxation time significantly. Small
molecules (such as water) tumble too rapidly to cause effective T1 relaxation. However,
when the water is in a partially bound or restricted state (as it is transiently bonded to
proteins and other macromolecules), its tumbling rate may be slowed to a rate near to the
Larmor frequency. Therefore, the T1 value of free water is very long and the “bound”
water is much shorter [51].
The magnetic field strength affects the T1 of different molecules in a different
way. For protons in highly mobile molecules (such as free water), the T1 value does not
change very much because the fraction of protons precessing at Larmor frequency is not
altered appreciably. For protons in molecules with intermediate or low mobility, the T1
will increase at higher field strength as the fraction of protons decreased significantly at
higher Larmor frequency. For most biological tissues, there is an empirical equation
suggesting that T1 increase approximately as B1/3 [51].

1.4.2 T1 Mapping Techniques
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Most currently available T1 mapping methods are based on one of 2 generic
methods: variable flip angles and sampling the saturation or inversion recovery curve.
1.4.2.1 Variable Flip Angle Sequence
T1 maps can be generated using T1-weighted images with variable flip angles.
The variable flip angle method can be performed with at least 2 gradient echo
acquisitions with different flip angles. The radio-frequency pulse diagram of this method
is shown in Figure 1-5. In this method, a pulse of tip angle θ is used to perturb the
magnetization, which is then left to partially relax back to its thermal equilibrium during
the short repetition time TR. As the excitation pulse angle is generally smaller than 90
degree, only a fraction of the thermal equilibrium magnetization is “tipped” into the
transverse plane. This transverse magnetization is then a function of both the pulse flip
angle and the amount of longitudinal relaxation that has occurred during the time interval
TR [44]. An echo is formed through the use of gradients. The transverse relaxation during
TE is described by the effective transverse relaxation time constant T2* and the signal
intensity SI for any pixel is given by

SI = CM 0 exp(-TE/T2* )

sin θ [1 − exp(− TR / T1 )]
1 − cos θ exp(− TR / T1 )

(1.3)

Where M0 is the net magnetization at thermal equilibrium; C is a dimensionless
constant representing the gain of the receiver circuit. In deriving Eq. (1-3), there are two
assumptions: the pulses are applied along the same axis and a steady state has been
reached. The variable flip angle method can be performed rapidly with 2 echo
acquisitions, each with a different flip angle (θ1, θ2) and keeping other parameters same,
which is called dual flip angle (DFA) method. Then T1 can be derived as
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T1 = −TR / ln(m)

(1.4)

SI 1
SI 2
−
sin θ1 sin θ 2
m=
SI1
SI 2
−
tan θ1 tan θ 2

(1.5)

Several limitations still exist for this method such as significant errors from B0
inhomogeneity caused by not using 180 degree pulses to refocus the echo and B1
inhomogeneity from a difference between actual flip angle and the prescribed flip angle.
The latter becomes more obvious at higher magnetic field strengths, such as 3T [47].

Figure 1-5: Variable flip angle, gradient-recalled echo pulse sequence
1.4.2.2 T1 Mapping with “Spin Echo” Inversion Recovery (IR- SE)
The pulse diagram for spin echo with an inversion prepulse is shown in Figure 16.This method uses an 180 degree pulse to invert the spins within the selected slice, then
a 90 degree pulse to tip the recovered magnetization at inversion time (TI) [44] and
another 180 degree pulse to form the spin echo. Sampling of the inversion recovery curve
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needs to be repeated multiple times with different inversion times. The repetition time
(TR) of the sequence must be long enough for the perturbed magnetization to return to its
thermal equilibrium before the next 180 degree pulse. The signal intensity of the final
image is proportional to the relaxed fraction of the magnetization during the TI:
SI = CM 0 exp(-TE/T2 )[1 - 2 exp(− TI / T1 )]

(1.6)

The first exponential term in Eq. (1.6) refers to the signal decay due to transverse
relaxation during echo time (TE); the second exponential term accounts for T1 relaxation
during inversion time interval TI. A T1 map can be generated by nonlinear, multiparametric, least-squares fitting to Eq. (1.6) for each pixel of the image.
IR-SE sequence is the conventional method to estimate T1 because it is not
affected by B0 inhomogeneity [44]. It has been known as the gold standard for
computing T1 in vitro with good accuracy. However, the repetition time of the sequence
must be very long, which means practically that the TR should be at least five times the
longest T1 to achieve ~99% recovery of that matter. This requirement is difficult to be
met in the imaging context, as the scanning time would be unacceptably long (eg, TR =
10 s in vivo). Furthermore, the imaging process needs to be repeated at least 5-6 times to
acquire several images with different TIs while keeping other sequence parameters same.
Therefore, a very long scanning time is necessary to ensure the acquisition of enough
data points for calculating T1. A major problem encountered in making accurate T1maps
based on a conventional IR-SE is the long acquisition time, making it unsuitable for
routine clinical purposes. To reduce the acquisition time, turbo spin echo inversion
recovery (IR-TSE) is usually used.
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Figure 1-6: Inversion recovery spin-echo pulse sequence diagram
1.4.2.3 T1 Mapping with “Look Locker” Inversion Recovery (LL)
The LL method has been developed to accelerate the data acquisition process
[52]. To calculate T1 more rapidly, it is desirable to sample the inversion recovery curve
multiple times after a single inversion, rather than once as in the conventional IR-SE
acquisition. The LL method employs a series of small flip angle excitation pulses after an
inversion pulse to sample the inversion recovery curve with different TIs. To disturb the
recovery curve minimally, usually low flip angles (7-15°) are used. The phase interval
between two inversion pulses should be long enough to allow magnetization to return
towards equilibrium by a sufficient pause. Look Locker has been used for cardiac
applications because of its fast acquisition. Although LL has been shown to be highly
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efficient, it suffers inaccuracies from the low flip angle RF pulses exciting the
magnetization intermittently and not reaching the equilibrium magnetization before the
next inversion pulse. Therefore, the T1 values are usually underestimated by the LL
method. Another problem is the fact that the images with different TIs are acquired at
different cardiac phases, therefore, manually tracking the myocardium among different
phases are necessary. In addition, images are acquired continuously throughout the
cardiac cycle and can be subject to cardiac motion [45]. Thus, a region of interest (ROI)
would need to be drawn in a segment of the myocardium and moved along with the
cardiac motion to calculate T1 in a focal area/lesion of the myocardium, which is still
challenging in clinical practice. Thus, the current predominant cardiac application of
Look Locker is to measure the global T1 in myocardium. This technique is not suited for
measuring T1 in regionally accentuated lesions, which may not be visible in all images
due to through-plane motion.
The measured data are assumed to follow a monoexponential recovery similar to
IR-SE signal recovery. The difference is the recovery curve is determined by an apparent
relaxation constant T1* (effective T1) not T1 in IR-SE:

 TI 
M Z = A − B ⋅ exp − * 
 T1 

(1.7)

Three-parameter nonlinear curve fitting using a Levenberg-Marquardt algorithm
is performed to calculate T1*. The true T1 is then calculated from T1* and the fitted
parameters A and B according to T1 = T1* ((B/A) – 1).

25

Figure 1-7: Look Locker inversion recovery pulse sequence diagram
1.4.2.4 T1 Mapping with Modified Look Locker Inversion Recovery (MOLLI)
MOLLI [45] was developed several years ago, and is a variant of LL. A series of
images with different TIs from multiple LL experiments are acquired in a fixed
acquisition window in the RR interval and then merged into one data set according to
their inversion times. Three-parameter nonlinear curve fitting is performed and T1 is then
calculated from T1* by using same equations used by LL method. The resulting T1 maps
provide good T1 accuracy and high reproducibility [46] over a wide range of T1s that
would cover the myocardial signal in both pre- and post-contrast agent injection
acquisitions.
MOLLI requires the data for one image to be acquired in a single shot, which
compensates for the cardiac motion problems of conventional LL at the expense of a
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usually inferior spatial resolution. Moreover, a long cardiac acquisition window may
result in the risk of cardiac motion artifacts. A very careful timing is necessary to place
the acquisition window in a quiescent period of the cardiac cycle, usually at the end
diastole phase.

Figure 1-8: Modified Look Locker inversion recovery pulse sequence diagram

1.5 Objective and Organization of the Thesis Work
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Specific remaining questions include evaluation of whether myocardial T1 values
are constant throughout the entire cardiac cycle [53-55]. Such an assumption has been
questioned by a recent study, which reported a cyclic variation in myocardial T1 in
healthy subjects at 3T [47]. Furthermore, the accuracy of T1 mapping is confounded by
several factors, such as the types of T1 mapping acquisition sequence, physiologic
parameters, and presence of contrast material. Lastly, validation of T1 mapping for
quantification of myocardial fibrosis is not sufficiently validated against histological
analysis of myocardial biopsy. In this thesis work, we have made efforts to address these
limitations.
The objective of this study is to evaluate T1 mapping techniques and develop an
accurate and fast T1 mapping technique with B1 mapping correction at 3 T. Our specific
aims were: 1) to evaluate whether there is clinically significant cyclic variation of
myocardial T1 at 1.5 T; 2) to evaluate the accuracy of myocardial T1 measurements
which may be dependent on characteristics of diseased tissues, heart rate, specific
features of the T1 mapping methods, and the absolute T1 value, which is different
between precontrast and postcontrast agent injection; 3) to evaluate whether the B1
mapping correction technique can improve the accuracy of T1 measurement with DFA at
3 T; 4) to correlate the noninvasive T1 mapping quantification of myocardial fibrosis
with the invasive biopsy analysis.
The fulfillment of these specific aims are detailed in the following chapters (2~5).
The main work of each chapter is outlined as follows: In Chapter 2, cyclic variation of
myocardial T1 value was evaluated by imaging 10 volunteers and 20 patients with
normal left ventricular (LV) function with MOLLI at 1.5 T. The T1 maps were obtained
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at end-systole (ES), mid-diastole (MD), and end-diastole (ED) during the cardiac cycle to
compare whether T1 changes at different cardiac time points.
In Chapter 3, we implemented and tested a fast T1 mapping method: dual flip
angles (DFA) sequence with B1 correction at 3 T. The available sequence on our MRI
scanner only allows acquiring one gradient echo image in one acquisition with a single
flip angle. The sequence is changed to acquire two images with two different flip angles
respectively in single acquisition using pulse programming. The T1 measurements with
2D and 3D DFA sequences were performed and the results showed that the single
acquisition 3D DFA with B1 correction produced significant improvement in measuring
a wide range of T1 values compared with no B1 correction at 3 T. The 3D DFA with B1
correction was then compared with the T1 measurements with the gold standard method
(IR-TSE), MOLLI and LL sequences.
In Chapter 4, Look Locker (LL) and modified Look Locker inversion recovery
(MOLLI) sequences for T1 mapping were compared in phantoms and in controls with
normal LV function, patients with HCM, and those with ICM. Based on the results from
Chapter 2, T1 value is consistent during the cardiac cycle. Therefore, only T1-weighted
images at end-diastole were acquired to minimize artifacts from the cardiac motion
because end-diastole is the most quiescent phase during the cardiac cycle. Phantoms were
imaged with 3 T1 mapping techniques (IR-TSE as reference, LL, and MOLLI). A total of
5 controls, 16 patients with HCM, and 5 patients with ICM were imaged at 1.5 T using
LL and MOLLI at 2 LV short-axis levels. T1 measurements were performed before and
after contrast injection with MOLLI and LL.
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In Chapter 5, histological analyses were correlated with T1 mapping results in
patients with HCM. T1 measurements with MOLLI sequence were performed precontrast
and postcontrast when the patients underwent MRI examinations. Myocardial ECV were
calculated from noninvasive T1 measurements. Myocardial myectomy specimens were
taken from the same patients during surgery. Collagen volume fraction was then
determined from histological analysis of myocardial biopsies. The ECV determined from
noninvasive T1 mapping technique was correlated with the collagen volume fraction
from invasive method.
Further, several future research directions were suggested based on the current
research in Chapter 6.

30

CHAPTER II
CYCLIC VARIATION IN MYOCARDIAL T1 RELAXATION TIME

2.1 Introduction

Spin-lattice (or T1) relaxation time has shown great potential in characterizing
myocardial fibrosis in the context of ischemia/infarction [38, 39] and infiltration (eg
amyloidosis) [40]. “Spin echo” inversion recovery (IR-SE) is the gold-standard for
computing T1 in vitro [44], but long acquisition times limit its routine use for clinical
cardiac applications.
A variety of methods have been developed to accelerate the image acquisition
speed. Most of these methods are based on one of two generic methods using multiple
T1-weighted scans: variable flip angle [47], and sampling of either saturation [44] or
inversion recovery curves [44, 45, 52]. The variable flip angle method can be performed
rapidly, but is subject to significant errors from B1 inhomogeneity [47]. The “Look
Locker” (LL) inversion recovery method has been applied to myocardial T1 mapping by
accelerating the data acquisition process [31]. With the LL method, manually tracking the
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myocardium is needed to calculate T1 because the images are acquired at different
cardiac phases. Furthermore, through-plane motion may compromise the accuracy of the
T1 map, especially for small structures, such as myocardial lesions. Modified Look
Locker inversion recovery (MOLLI) [45] is a variant of LL by improving the acquisition
process to allow a series of images be acquired in a fixed acquisition window between
two R-waves showed in the electrocardiogram (ECG) (RR interval).
In most T1 mapping applications, T1 maps are typically created from images
acquired either at end-diastole, to minimize cardiac motion artifacts (eg MOLLI), or
throughout the cardiac cycle, to reduce scan time (eg LL). There is an underlying
assumption of these methods that the myocardial T1 value is constant throughout the
cardiac cycle [9-11]. However, this assumption has been questioned in a recent study [5],
which reported cyclic variation of myocardial T1 at 3 T of 70% in the septum and 43% in
the lateral wall from end-diastole (ED) to end-systole (ES) in healthy volunteers.
Myocardial blood volume (MBV) variation during the cardiac cycle was considered to
contribute to the change of T1. In this study, the dual flip angle technique was used to
generate cine myocardial T1 maps. The distribution of T1 was concluded to be
heterogeneous throughout the cardiac cycle and could cause large variation in the mean
T1. Therefore, plots of mean T1 are not optimal for comparison between subjects.
However, the T1 estimation obtained by this dual flip angle technique is very sensitive to
the amplitude of the RF field (B1) inhomogeneity, and the geometry and electrical
properties of the human body, which can lead to errors in T1 value calculation. This error
is more obvious at higher magnetic field strengths, as in this study performed at 3T.
However, the MBV is only about 6% to 15% of the left ventricular (LV) mass, indicating
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that the change of T1 value from MBV may not be pronounced enough to be detected, as
the percentage of the change is within the standard deviation of the technique.
Development and optimization of clinical T1 mapping sequences to accurately
calculate T1 values of the heart are of particular importance for the diagnosis of
myocardial diseases. Therefore, it is important to evaluate T1 values at different points in
the cardiac cycle to determine whether similar cyclic T1 variation is seen at 1.5T, which
is more widely used in routine clinical diagnosis. T1 values were evaluated at different
points in the cardiac cycle to determine whether similar cyclic T1 variation is seen at
1.5T using MOLLI, and the possible effect on the T1 mapping methods that assume
constant myocardial T1 during the cardiac cycle.

2.2 Materials and Methods

2.2.1 Subjects Population

This was a prospective study in subjects without known heart disease. After
Institutional Review Board approval and written informed consent was obtained from all
study subjects, 10 human volunteers (n = 10, 5M/5F, age 30 ± 8 years), and 20 patients (n
= 20, 16M/4F, age 52 ± 16 years) with normal left ventricular function were recruited in
the study. Exclusion criteria will include pregnant females; age less than 18 years, as well
as absolute contraindications to MRI (eg, pacemaker).
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2.2.2 Imaging Procedure

Subjects underwent MRI examinations using a clinical 1.5 T scanner (Achieva
XR, Philips Medical Systems, Best, NL). Subjects were first screened for MRI eligibility;
all subjects completed the standard Cleveland Clinic Hospital System (CCHS) Safety
Screening Form for MRI Patients, which is given to all patients referred clinically for
MRI. ECG leads were placed on each subject’s chest in order to synchronize image
acquisition with heart motion. At the beginning of all studies, long-axis cine images
(vector ECG-gated steady-state free precession; repetition time ms/echo time ms, 3.0/1.5;
matrix, 144 ×150; slice thickness, 10 mm; 30 phases) were acquired. Then, MOLLI
sequences were performed at end-systole (ES), mid-diastole (MD), and end-diastole (ED)
of the cardiac cycle at two short-axis levels (mid-cavity, apical-cavity). The MOLLI
sequence requires multiple single-shot scans within one breath hold (approximately 12-20
seconds). The MOLLI pulse sequence consists of three successive inversion-recovery
prepared ECG-triggered LL experiments (LL1, LL2, and LL3), which were carried out
with three, three, and five single-shot readouts, as described previously [45]. Undisturbed
magnetization recovery was allowed for about 3 seconds between each LL experiment,
with variation dependent on the subjects’ heart rate, and the reconstruction and
preparation time of the MR scanner. Each of the three LL experiments started with a nonslice-selective adiabatic 180° pulse, and then the first single-shot readout was performed
at inversion time (LL1 ≈ 40 ms, LL2 ≈ 200 ms, and LL3 ≈ 350 ms) and at trigger delay
time (TD) after the previous R-wave. Subsequent images were acquired at time TD after
every R-wave in consecutive heartbeats, until the final number of images for each LL
experiment was acquired, resulting in a set of 11 source images with their different
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effective inversion times. Data acquisition consisted of a single-slice, single-shot, turbofield echo (TFE) pulse sequence combined with SENSE with a reduction factor of 2,
number of lines of k-space (TFE factor) = 49, dummy acquisitions = 13, partial Fourier
acquisition, flip angle = 10°, repetition time (TR) = 3.9 ms, echo time (TE) = 1.95 ms,
field of view (FOV) = 380 ×342 mm2, matrix = 240 ×151, measured pixel size = 1.58
×2.26 mm2, slice thickness = 8 mm, and acquisition window = 191.1 ms.

2.2.3 Data Analysis

By reordering these source images according to their inversion time and merging
them into one data set, T1 values can be computed for every pixel by three-parameter
nonlinear curve fitting using a Levenberg-Marquardt algorithm y = A – B exp (–t/T1*).
T1 is then calculated from effective T1 (T1*) by T1 = T1* ((B/A) – 1) [45].
Reconstruction of T1 maps from MOLLI was performed off-line using software written
in Matlab (The MathWorks, Natick, MA, USA). The T1 values at different time points
during the cardiac cycle were also compared with each other.
A region of interest (ROI) was manually drawn in 1 image, copied to the
remaining images. Curve fitting was performed using signal intensity from manually
drawn ROI using Matlab to obtain the mean T1 value within the corresponding ROIs.
Precontrast myocardial T1 values of two short-axis levels were compared to assess
agreement of T1 values during the cardiac cycle. Regional myocardial T1 properties were
further evaluated using an ROI-based approach in every subject. Four ROIs in the mid-
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myocardium (septal, inferior, lateral, and anterior) were drawn according to Figure 2-1 to
fit the mean signal intensity of each ROI.

Figure 2-1: Left ventricular segmentation [56]

2.2.4 Statistical Analysis

Analysis of variance (ANOVA) was used to assess statistical significance of
differences between time points and regions including myocardial T1 values from all
subjects. All results are expressed as mean T1 values ± standard deviations (SD). P<0.05
was considered statistically significant.
For the primary analysis, the mean of the myocardial T1 values across the four
locations was used in the statistical analysis. The distribution of the mean myocardial T1
values was examined and found to follow a normal distribution reasonably well. A oneway repeated measures ANOVA was performed for both the middle and apical levels.
The null hypothesis was that the T1 values are the same across the three time points; the
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alternative hypothesis was that the T1 values are not the same. A significance level of
0.05 was applied. If the null hypothesis was rejected, then a paired t-test was used to
examine the differences between each of the time points. In secondary analysis, repeated
measures ANOVA were performed for each location around the left ventricle: septal,
inferior, lateral, and anterior wall. A significance level of 0.05 was applied.

2.3 Results

T1 maps were generated using software written in Matlab (The MathWorks,
Natick, MA, USA) calculating T1 value pixel-wisely. Figure 2-2 shows representative T1
maps from a volunteer at 3 time points in the cardiac cycle. The trigger delays were 285
ms (ES, top), 520 ms (MD, middle) and 756 ms (ED, bottom). The color of myocardium
on each T1 map is similar. Visually, there is no different among cardiac phases. Regional
myocardial T1 values were further evaluated using ROI-based approach in healthy
volunteers. Four ROIs in the septal, inferior, lateral, and anterior wall of the heart were
drawn to fit the mean signal intensity of each ROI. The curve fitting examples of four
regions of interest were shown in Figure 2-3.
A linear regression analysis was performed for precontrast T1 values and heart
rate, as shown in Figure 2-4, with T1 = -3.23×HR + 1160.40 and R2=0.62. Table 2-1
shows global T1 values obtained for the 10 volunteers before and after application of the
correction factors. Mean T1 value before correction was T1 = 961.2 ± 36.3 ms; after heart
rate normalization to 60 bpm, T1 = 966.6 ± 22.4 ms. Correction for heart rate was then
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Figure 2-2: T1 maps at 3 points in the cardiac cycle from a volunteer
applied to each subject based on the linear fit. The range of uncorrected T1 values for all
ROIs was 791-1034 ms in this study. After heart rate correction, the range of T1 values
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Figure 2-4: Myocardial T1 values of 10 healthy volunteers showed a negative linear
relationship to heart rate (R2=0.62)
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was 859-1054 ms. Our results are consistent with previously reported T1 values
measured at end diastole (862-1105 ms) [46] using the MOLLI sequence.
Table 2-1: Precontrast T1 values (ms) for 10 normal volunteers before and after
correction for variation in heart rate

Volunteer
number

Heart rate
(bpm)

T1 uncorrected
(ms)

T1 corrected
(ms)

1

61

998

1003

2

63

932

941

3

65

944

961

4

57

961

951

5

52

1011

986

6

83

882

956

7

56

965

952

8

68

978

1002

9

57

958

948

10

55

981

965

961 (36)

967 (22)

Mean ( SD)

Table 2-2 summarizes the means and standard deviations of the T1 values at each
time point at the middle and apical levels. As shown in Figure 2-5, the T1 values differed
significantly with cardiac cycle phase (P = 0.017) at the middle level. Specifically, the
T1 values at diastole are greater than at end-systole (P = 0.037; 95% CI for the difference
in T1 values is [0.9, 26.7]), and the T1 values at end-diastole are greater than at endsystole (P = 0.004; 95% CI is [9.1, 39.0]). The T1 values at diastole and end-diastole do
not differ significantly (P = 0.139). For the apical level, the T1 values differ significantly
over time (P = 0.001) as shown in Figure 2-5. Specifically, the T1 values at diastole are
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greater than at end-systole (P = 0.048; 95% CI is [0.1, 31.2]), and the T1 values at enddiastole are greater than at end-systole (P < 0.001; 95% CI is [14.0, 38.9]). The T1
values at diastole and end-diastole do not differ significantly (P = 0.108).
Table 2-2: Mean (SD) of myocardial T1 values at three time points

Diastole

End-diastole

End-systole

Middle level

946.8 (35.9)

956.5 (42.4)

933.0 (32.6)

Apical level

950.4 (42.4)

961.2 (38.7)

934.8 (42.4)

Comparison of regional T1 values at each ROI for each time point for both the
middle and apical levels was shown in Figure 2-6. Table 2-3 summarizes the means and
standard deviations of the T1 values at each location for each time point for both the
middle and apical levels. At septum, the T1 values do not differ significantly over time
(P = 0.126) for the middle level and the T1 values differ significantly over time (P =
0.014) for the apical level. Specifically, the T1 values at end-diastole are greater than at
end-systole (P = 0.005; 95% CI is [8.2, 42.6]). The T1 values at diastole and end-diastole
are not significantly different (P = 0.055), and the T1 values at diastole and end-systole
are similar (P = 0.840). At inferior wall, the T1 values do not differ significantly over
time (P = 0.122) for the middle level and the T1 values differ significantly over time (P =
0.016) for the apical level. Specifically, the T1 values at end-diastole are greater than at
end-systole (P = 0.009; 95% CI is [9.2, 60.2]) and greater than at diastole (P = 0.017;
05% CI is [3.5, 33.3]). The T1 values at diastole and end-systole are similar (P = 0.167).
At lateral wall, the T1 values do not differ significantly over time (P = 0.169) for the
middle level and the T1 values do not differ significantly over time (P = 0.095) for the
apical level. At anterior wall the T1 values do not differ significantly over time (P =
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0.072) for the middle level and the T1 values do not differ significantly over time (P =
0.197) for the apical level.
Comparisons between the four locations, there are no differences in the T1 values
at the middle level at diastole (P = 0.837), end-diastole (P = 0.778), or end-systole (P =
0.690). Similarly, there are no differences in the T1 values at the apical level at diastole
(P = 0.611), end-diastole (P = 0.206), or end-systole (P = 0.635).
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Figure 2-5: Comparison of T1 values at 3 different time points at middle and apical levels.
‡=Statistical significance of changes between time points (P<0.05 vs ES)
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Figure 2-6: Comparison of regional T1 values at 3 different time points at middle and
apical levels. *=Statistical significance of changes between time points (P<0.05 vs ED)
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Table 2-3: Mean (SD) of myocardial T1 values at three time points by location

Diastole

End-diastole

End-systole

Septum

948.4 (61.0)

955.1 (51.9)

933.9 (50.1)

Inferior

948.5 (49.9)

963.5 (48.4)

937.1 (43.3)

Lateral

942.3 (43.0)

953.5 (70.4)

926.5 (43.5)

Anterior

948.2 (42.7)

954.2 (52.1)

934.6 (40.8)

Septum

940.8 (56.9)

963.7 (49.6)

938.3 (56.0)

Inferior

957.4 (53.1)

975.9 (54.8)

941.2 (50.4)

Lateral

953.7 (69.2)

956.3 (64.0)

928.6 (59.3)

Anterior

949.4 (49.7)

948.9 (52.1)

930.9 (48.4)

Middle level

Apical level

2.4 Discussion

In this study, myocardial T1 values from 10 volunteers and 20 patients were
measured using MOLLI at three different time points of the cardiac cycle. At both the
middle and apical levels, end-systolic T1 values differed significantly from mid-diastole
and end-diastole. However, the T1 values at mid-diastole and end-diastole did not differ
significantly from one another. Also, the largest difference between time points was
approximately 39 ms, which is within the standard deviation of the T1 mapping technique
in use. Furthermore, our results are similar to those of a recent study [46] which reported
T1 values from 862-1105 ms using MOLLI.
Although we found that differences in T1 were statistically significant among
time points, we do not feel these differences are clinically significant. For instance, some
of the variation in our results could be explained by increased cardiac motion at end
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systole relative to mid-diastole and end-diastole. Overall, these results demonstrate that
T1 values are approximately constant throughout the cardiac cycle at 1.5 T; they suggest
that the magnetic properties of myocardial tissue do not change significantly throughout
the cardiac cycle, and T1 quantification methods such as Look Locker should be valid at
1.5 T.
A recent study examined the effect of cardiac cycle on myocardial T1 at 3 T using
MOLLI [57]. Their results showed that the precontrast T1 values were 1% longer
(approximately 15 ms) at diastole than systole at 3 T. Similar to the current study, this
difference, although statistically significant, was not clinically significant. Furthermore,
this previous study was performed at different field strength (3 T) from the current study,
using a balanced steady-state free precession technique, which could explain the modest
differences in results.
Our results disagree with the large variation in myocardial T1 at 3 T observed by
Wansapura et al [47], who reported a drop in T1 during systole of 70% in the septum and
43% in the lateral wall. However, their study relied on a dual flip angle acquisition
technique, and the variations they observed may result from the inflow of unsaturated
spins during the contractile heart motion. Wansapura et al [47] concluded that changes in
myocardial blood volume during the cardiac cycle contributed to the cyclic T1 variation
they observed. However, myocardial blood volume is only about 6%-15% of the left
ventricular mass. The change of T1 value from MBV may not be pronounced enough to
be detected, as the percentage of the change is within the standard deviation of the
technique. The relationship between tissue volume and vascular volume fluctuations is
complex, since the capillary walls are highly permeable to water. According the
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physiology of myocardial blood flow and previous studies, systolic reduction in
myocardial volume [58-61] has been explained as a result of blood that is squeezed out of
the coronary vasculature within the myocardium. The myocardial volume decreased
during systole and reached the minimum near aortic valve closure or end systole (ES).
The changes in myocardial volume during the cardiac cycle have not attracted much
attention, primarily because the myocardial blood flow measured by microsphere
techniques [62] would predict systolic myocardial volume reduction on the order of only
1% in canine using a motion-encoding MRI technique [60]. Toyota et al [63] observed in
vascular casts of rat hearts a vascular volume change equivalent to 7–8% of the tissue
volume between systole and diastole. These studies reflect the decrease of myocardium
volume at ES; however, they do not seem significant enough to cause a 43%-70% drop of
T1 values. In contrast, in both the current study and that of Kawel et al [57], the decrease
in T1 from diastole to systole does seem to correspond with these reported systolic
changes in myocardial blood volume. There is an animal study using three-dimensional
VFA T1 mapping of the mouse heart showed that T1 values ate end-diastole were almost
equal to those at end-systole at 9.4 T preclinical MRI scanner [64].
The big difference of T1 values across the regions of interest was found by
Wansapura et al [47], concluding this is caused by the larger difference in MBV in the
septum between ED and ES compared to that in the lateral wall. However, there was no
such big difference in our study. In the study of Wansapura et al [47], the dual flip angle
technique was employed. The dual flip angle technique allows for fast imaging, but is
prone to errors in absolute T1 measurements caused by B0 and B1 inhomogeneity,
especially at higher field strength, such as 3 T. In addition, the geometry and electrical
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properties of the human body can lead to errors in T1 with this technique. For instance,
Sung et al [65] reported B1 field inhomogeneity over the LV yielded a flip angle
distribution of 34º to 63º across the LV for a nominal flip angle of 60º, with the average
flip angle about 20% lower than 60º. Although the impact on T1 accuracy is known, B1
correction of measured T1 was not employed by Wansapura et al [47].
In contrast to the dual flip angle technique, MOLLI is an established method to
measure the myocardial T1 and has been more widely used in both 1.5 T and 3 T studies
[42, 46, 48, 50, 66]. The normal range of human myocardial T1 values has been
established with MOLLI [48] and our results using MOLLI agree well with the previous
studies of normal myocardial T1 values [46]; also, we found a negative relationship
between T1 values and heart rate, similar to previous study [31]. Although the correction
equation we obtained differs from previous studies [31, 46], this may result from
numerical differences in the source data due to differences in sample size and patient
population.
Development and optimization of clinical myocardial T1 mapping sequences are
of particular importance for the diagnosis of myocardial diseases. Such significance
warrants further investigation of the myocardial T1 mapping at 3 T because CMR at 3 T
is a rapidly maturing field and becomes more widely used. However, cardiac MR at 3 T
is challenged by the increased inhomogeneity of static magnetic field B0 and transmit
radiofrequency (RF) field B1. B0- and B1- map will be necessary to accurately measure
the myocardial T1 values at 3 T. SDAM B1-map [67] has been further developed to
simultaneously acquire B0- and B1- map in the heart within one breath-hold, which
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allows the future study of cyclic variation of myocardial T1 using dual flip angle
techniques with B1 map correction at 3 T and to be compared with MOLLI.

2.5 Conclusion

The MOLLI sequence was used to study the cyclic variation of myocardial T1 at
1.5 T. Although the statistically significant decrease from the diastole to systole may be
caused by myocardial blood volume decrease, the decrease is not thought to be clinically
significant, as the difference is within the standard deviation of the technique.
Furthermore, there were no significant differences among different regions of interest of
myocardial T1 values. Therefore, the magnetic properties of myocardium are fairly
constant, and the accuracy of Look Locker technique should not be significantly affected
from the consistently acquiring images during the cardiac cycle.
Our study is limited to 1.5 T scanner and precontrast myocardial T1 value
obtained with MOLLI. The significant drop of T1 value from ED to ES in the 3 T study
was performed with dual flip angle, which is a different technique from our study. This
dual flip angle technique will be studied in next chapter to see its difference from
MOLLI. In addition, although the same cardiac phase was set to obtain the MOLLI
images in our study, the difference may occur among the images because every heart beat
is different, especially when the subject has unstable cardiac frequency.
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CHAPTER III
DUAL FLIP ANGLE WITH B1 MAPPING CORRECTION

3.1 Introduction

Longitudinal relaxation time, or T1, is one of the fundamental physical variables
governing image contrast in magnetic resonance imaging [6]. T1 mapping is of interest in
a range of areas including dynamic contrast enhanced studies of tissue perfusion,
diagnosis of neurological diseases, and quantitative imaging for multi-site studies. As a
result, quantitative mapping of T1 has a long history, and a wide variety of methods have
been developed [68]. Comparing with those techniques based on saturation or inversion
recovery techniques, variable flip angle (VFA) method can measure T1 relaxation times
rapidly and accurately from a set of two or more spoiled gradient recalled-echo (SPGR)
images. Therefore, VFA method is a promising method to meet the clinical requirement
of time frame [69, 70]. The accuracy of this method has been tested to be similar to that
achieved with conventional and accelerated techniques but with a significant reduction in
imaging time [71]. Furthermore, compared to spin echo techniques this approach has the
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advantage of low power deposition. The VFA spoiled gradient recalled echo approach
was shown to be a practical alternative to conventional methods, providing better speed
[70]. The simplest and fastest T1 measurement method is the dual flip angle technique.
A dominant source of error in the VFA approach is inaccurate knowledge of the
flip angles due to transmit field B1 inhomogeneity. The method is known to be sensitive
to transmit field (B1) inhomogeneity and can result in significant systematic errors in T1
estimates, especially at high field strengths. Although the impact on T1 accuracy is
known [72], correction of measured T1 has been reported in only a few studies [73, 74].
Due to the complexity and long scan time requirements of mapping the B1 field, the B1
map is difficult to be acquired for cardiac imaging. Ideally, an angle set will yield the
highest and most uniform precision across large T1 ranges while maintaining accuracy.
To optimize the VFA method for both accuracy and precision, the influence of imperfect
transmit fields and selection of flip angles should be considered [70]. The main challenge
is to improve the accuracy of the VFA approach without sacrificing speed. To achieve
optimal accuracy in VFA measurements requires careful selection of pulse sequence
parameters and precise knowledge of the spatial variation in RF flip angle which can be
obtained by B1 mapping. However, in only a few studies [20-25] correction has been
reported mostly in brain imaging [20, 22, 25], mainly due to the complexity and long
scan time requirements of mapping the B1 field. Although many B1 mapping methods
have been developed to date, no single one has been in widespread application.
With VFA technique, more flip angles will increase the accuracy of the method;
however, the scanning time will also increase. Dual flip angle (DFA) is the simplest way
of VFA with only 2 different flip angles, which can achieve the highest efficiency over a
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narrow T1 range. In chapter 1, MOLLI was used to evaluate the cyclic variation of
myocardial T1 values. Our results are different from a study at 3 T using DFA technique.
To understand better about the DFA method, and know how much the B1 inhomogeneity
can affect the accuracy of T1 measurement at 3 T. The aim of this study was to develop a
fast T1 mapping technique for accurate T1 quantification using the DFA method with fast
B1 mapping to correct for spatial variations of the nominal FA at 3 T.

3.2 Theory

The VFA technique is based on the consecutive application of T1-weighted
spoiled gradient-echo (T1 fast-field echo (T1-FFE)) sequences using different flip angles
[75]. The theoretical signal intensity S of a T1-FFE sequence is a function of the
equilibrium longitudinal magnetization M0, relaxation times T1 and T2, echo time (TE),
repetition time TR (TR), and flip angle [71, 76]:

S = M0

(1 − E1 ) sin α
1 − E1 cos α

(3.1)

Where E1 = exp(−TR / T 1) .
Keeping TR and TE constant and measuring the signal induced by different FAs,
one can find a straight line characterized by slope a = E1 and intercept b = (1- E1) by
linear regression.
S
S
= E1
+ M 0 (1 − E1 )
sin α
tan α
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(3.2)

T1 is then easily calculated as:

T1 = −TR / ln( E1 )

(3.3)

A correct calculation of T1 is only valid if the transverse magnetization is
completely spoiled, longitudinal magnetization has reached a dynamic equilibrium
(steady state), and the amplitude of the radiofrequency field (B1) is homogeneous over
the complete field of view (FOV). Especially for a large FOV and at high magnetic field
strengths, B1 field inhomogeneities represent a dominant source of error in the VFA
approach [70].

3.2.1 Choice of Flip Angles

Achieving the best precision for the T1 range of interest requires optimally
selecting flip angles, but the selection process remains complex, particularly for multiple
angles. However, a couple of key results from previous work on this topic serve as useful
guidelines [68, 70, 71, 76, 77].
Wang et al [78] reported that optimum T1 precision occurs when the TR/T1 ratio
is approximately 1.1:1. Their results showed that the precision of two optimized angles
can be achieved as the precision obtained using 10 flip angles with 5-fold reduction in
imaging time [78]. A simple one-step method for determining the angles was proposed
for a particular TR/T1 [71].
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To estimate T1 from two signal intensities/points on the regression line
accurately, the further the two points are separated along the line will be better if each
point suffers the same uncertainty.
This separation along the ordinate can be defined as normalized dynamic range
(DR) of the regression line, given by:

DR =

Sα 2
Sα 1
−
M 0 sin(α 2 ) M 0 sin(α 1 )

(3.4)

Where α1 and α 2 are the two flip angles and Sα1 and Sα 2 are the signal
intensities associated with α1 and α 2 .
However, the data points may not suffer the same uncertainty; rather, the
precision depends on the location of the points along the line and generally decreases as
the two points move away from the midpoint (defined by the location of the peak of the
signal curve and given by Ernst signal ( Sα E )). This means that the precision can be
related to the fractional signal of the points (FS).

FS = ( Sα1 + Sα 2 ) / 2Sα E

(3.5)

The two optimum flip angles are derived by maximizing the product of DR × FS .
Besides determining the two ideal angles by searching for maxima in the product
of DR × FS , analytically predicting the optimal dual angles is possible by simplifying FS
to f:

f = FS = Sα1 / Sα E = Sα 2 / Sα E
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(3.6)

T1 precision is maximized by choosing the flip angles such that Sα1 = Sα 2 =
0.71 Sα E at f = 0.71 [71].
The solution for the two optimal angles can be written as:

 f 2 E ± (1 − E 2 ) 1 − f 2 
1
1



1 − E12 (1 − f 2 )



α = cos −1 

(3.7)

Therefore, when imaging for a single T1, precision can be optimized using two
“ideal” angles, defined as those whose signals are 71% of the Ernst angle signal.

3.2.2 Transmit Field B1 Imaging

The transmit field B1 of a volume coil may arise substantial inhomogeneity when
imaging at higher field strengths above 1.5 T. The distribution of the magnetic
radiofrequency (RF) field B1 has an important influence on image quality in magnetic
resonance imaging. In particular, inhomogeneities of the RF field are an essential source
of error for quantification of MR parameters in MRI [79]. For the successful application
of imaging and detection methods using a specially designed RF field, it is essential to
know the accurate B1 distribution within a tissue sample. In general, the B1 field in
whole body systems needs to be determined for each investigated object because induced
RF eddy and displacement currents account for remarkable differences between the field
of an empty and a loaded coil [80]. The induced currents depend on the shape of the
object, its electric properties, the resonance frequency, and the polarization of the used
RF coil [80]. Therefore a method for B1 determination using image data is highly
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desirable. An approach to account for this inhomogeneity is to map the B1 field
distribution.
A wide variety of amplitude of RF field (B1) mapping methods has been
developed to date [3]; however, no single one has emerged yet in widespread application
[81]. Generally, B1 mapping methods fall into two classes: signal magnitude or signal
phase based. The majority of B1 mapping methods depend on changes in signal
magnitude based on RF flip angle. Existing methods in this category include fitting
progressively increasing flip angles [82], stimulated echoes [83], image signal ratios [84],
signal null at certain flip angles [85], and comparison of spin echo and stimulated echo
signals [86]. These methods suffer from combinations of the following problems: T1
dependence; long acquisition times, mainly from acquiring many images and/or a long
pulse repetition time (TR) to mitigate the T1 dependence; inability to use some of these
methods with slice selection or in a multislice acquisition; inaccuracy over a large range
of B1, especially at low flip angles or flip angles close to 90° or 180°; and large RF
power deposition in the case of B1 mapping sequences based on large flip angles or reset
pulses to mitigate the T1 dependence. The most simple and straightforward of the B1
mapping methods are dual-TR method and double-angle method.
3.2.2.1 Dual TR Method (DTR)
The DTR B1 mapping technique is based on a T1-FFE sequence with a fixed flip
angle and two alternating TRs (TR1 < TR2) [76, 87]. The ratio r of the observed gradientecho signals STR1 and STR2 is a function of α, TR1, TR2, and T1:

r=

S TR1 1 − E12 + (1 − E11 ) E12 cos α
=
S TR 2 1 − E11 + (1 − E12 ) E11 cos α
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(3.8)

Where E11 = exp (-TR1/T1) and E12 = exp (-TR2/T1)
Based on this equation, the flip angle α is calculated as:


 1 − E11  

 1 − r
 1 − E  


12 
α = arccos

 rE −  1 − E11  E 
 11  1 − E  12 

12 



(3.9)

If the first-order approximation can be applied to exponential terms in Eq. (3.9),
exp (-TR/T1) ≈ 1-TR/T1, it can be simplified as:






1 − rn
α = arccos

 r 1 − TR1  − n1 − TR2  
 
T1  
T1  
 

(3.10)

Where n = TR1/TR2.
Assuming that 1-TR1/T1 ≈ 1 and 1-TR2/T1≈1 for TR1, TR2«T1 the calculation
of the flip angle becomes independent of T1 and is only a function of the ratios of the
measured signals r and the TRs n:
 1 − rn 

 r−n 

α = arccos

(3.11)

3.2.2.2 Double Angle Method (DAM)
The DAM method is specially designed for the in vivo measurement of the B1
field distribution in several cross sections in whole body systems within a few minutes
[79]. Between the modulus of the active RF field B1(x) and the flip angle a(x) of an
amplitude modulated RF pulse the following well known relationship with the pulse
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shape f(t), the pulse duration time tp, and the gyromagnetic constant γ is given
approximately [88]:

α ( x) = γB1 ( x) ∫

tp / 2

−t p / 2

f (t )dt

(3.12)

Where the x represents spatial position.
Two images are acquired with two different prescribed flip angles (α1(x), α2(x))
with the following relationship:

α 2 ( x) = 2α 1 ( x)

(3.13)

The ratio of the corresponding image signal intensities I1(x)/I2(x) of two spin
echo images measured with identical all other signal-affecting sequence parameters but
different nominal excitation angles given by [84]:
I 2 ( x) sin α 2 ( x) f 2 (T1 , TR )
=
I1 ( x) sin α 1 ( x) f1 (T1 , TR )

(3.14)

This ratio is independent of the coil sensitivity, the spin density, and the
transversal relaxation time T2(x). With a repetition time TR ≥ 5T, the longitudinal
relaxation terms become equal 1.0 and the ratio depends only on the flip angles. T1max is
the longest Tl time occurring within the investigated object. If the effects of T1 and T2
relaxation can be neglected, the flip angle distribution α1 (x) can be calculated by the new
relationship [79]:

α 1 ( x) = arccos

I 2 ( x)
2 I 1 ( x)

(3.15)
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Thus, the DAM allows the determination of α1(x) and consequently also of B1 (x)
of an RF coil loaded with an arbitrary object. The disadvantage of this method for in vivo
application is an extended scan time resulting from the condition TR ≥ 5T1max.
However, most double-angle approaches have been limited by the requirement of
long TRs and therefore long imaging times and motion compensation issues, which
restricts the method to be applied in heart. Recently, saturated double angle method
(SDAM) [84] for rapid B1 mapping has been introduced to map B1 field rapidly covering
the heart within a single breath-hold. It combines the double angle method with a B1insensitive magnetization-reset sequence used for saturation of the magnetization. This
technique allows the B1 correction of myocardial T1 measurements using dual flip angle
method in the future.

3.3 Materials and Methods

3.3.1 T1 Measurement with IR-TSE

Liquid samples with different concentrations of gadopentetate dimeglumine
(Magnevist; Schering, Berlin, Germany) doped with distilled water were prepared with a
range of T1 values representing precontrast and postcontrast myocardial T1 values at 3 T.
These phantoms were imaged on a 3 T scanner (Ingenia; Philips Medical Systems, Best,
The Netherlands) with the gold standard of T1 mapping technique (IR-TSE). The scan
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parameters were TE = 70 ms, TR = 10000 ms, TI = [50, 100, 200, 400, 800, 1400, 2200,
3500, 5000] ms. TSE factor = 7. FOV = 230 × 184 mm2, pixel size = 0.6 × 0.7 mm2, slice
thickness = 4 mm.

3.3.2 Choice of Flip Angles for DFA Method

Achieving the best precision for the T1 range of interest requires judicious
selection of flip angles [70]. In order to maximize the SNR in the T1 map, the pair of flip
angles which minimizes this expression has to be found numerically. The human
myocardial T1 is about 1170 ms, for TR = 6.4 ms, the product of DR×FS reaches its
maximum for the optimum FAs ( α1opt = 2°, α 2 opt =14°) as shown in Figure 3-1.

3.3.3 T1 Measurement with DFA and LL Methods

The DFA sequence is based on the consecutive application of fast field echo
sequences. In our study, this sequence was changed to realize 2 dynamic scans with two
optimal flip angles determined with Eq. (3.7) in one acquisition.
T1-weighted images were acquired using a dual flip angle 2D spoiled gradient
echo protocol with the following parameters: TR/TE = 6.4/3.7 ms, FA1/FA2 = [3°, 15°],
FOV = 340 × 384 mm2, pixel size = 1 × 1 mm2, slice thickness = 6 mm.
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Figure 3-1: Contour plots for determining the optimal flip angles for TR = 6.4 ms and T1
= 1170 ms
Then, T1-weighted images were also acquired using a dual flip angle 3D spoiled
gradient echo protocol with the following parameters: TR/TE = 6.4 ms/3.7 ms, FA1/FA2
= [2°, 11.6°], [2.5°, 14.2°], [3°, 15°], [3.1°, 17.5°], FOV = 340 × 384 mm2, pixel size =
0.6 × 0.7 mm2, and slice thickness = 6 mm.
All images were acquired on 3 T Ingenia MR Systems (Philips Medical Systems,
The Netherlands) with anterior and posterior coil. A commercially available cardiac B1calibration sequence, which is based on saturated dual angle method (SDAM), was
performed with a simulated ECG signal. The imaging parameters were TE = shortest, flip
angle = 60°, TR=1 heart beat.
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T1 measurements with LL sequence were performed with the following scan
parameters: flip angle, 10°; repetition time (TR), 7.7 ms; echo time (TE), 3.2 ms;
measured pixel size, 2 ×2 mm2; and slice thickness, 10 mm. After a 180° radiofrequency
prepulse triggered by the R peak of ECG, gradient-recalled echo images (number of
images dependent on the patient’s heart rate) were acquired throughout the cardiac cycle,
with a phase interval of approximately 25 ms between images.

3.3.4 T1 Measurement with MOLLI and LLN Methods

T1 measurements with MOLLI and LLN were performed on 3 T Achieva MR
Systems (Philips Medical Systems, The Netherlands) Eleven MOLLI images were
acquired from 3 successive IR-prepared, ECG-triggered LL experiments (LL1, LL2, and
LL3) with 3, 3, and 5 single-shot readouts, respectively. Each of the LL experiments
started with a 180° prepulse; the first single-shot readout was performed at inversion time
(LL1 ≈ 130 ms, LL2 ≈ 267 ms, and LL3 ≈ 350 ms) and at trigger delay time (400 ms)
after the previous R-wave. The scan parameters were as follows: flip angle, 35°; TR, 3.9
ms; TE, 1.95 ms; SENSE reduction factor, 2; measured pixel size, 1.9 × 2.3 mm2; slice
thickness, 10 mm; and acquisition window, 191.1 ms. LLN sequences were performed
with the following scan parameters: flip angle, 10°; repetition time (TR), 7.7 ms; echo
time (TE), 3.2 ms; measured pixel size, 1.9 ×1.7 mm2; and slice thickness, 10 mm. After
a 180° radiofrequency, 21 gradient-recalled echo images were acquired with a phase
interval of approximately 80 ms between images (this is main difference between LL and
LLN).

61

3.3.5 Data Analysis

The T1 calculation for IR-TSE is by three-parameter nonlinear curve fitting using
a Levenberg-Marquardt algorithm is performed pixel-wise for y = A – B exp (–t/T1*). T1
is then calculated from effective T1 (T1*) by T1 = T1* ((B/A) – 1) [7]. Reconstruction of
T1 maps was performed off-line using software written in Matlab (The MathWorks,
Natick, MA, USA).
For MOLLI and LL sequences, curve fitting was performed using signal
intensities from manually drawn ROIs using Matlab (The MathWorks, Natick, MA,
USA) to obtain the mean T1 value within the corresponding ROIs.
For the DFA method, the apparent T1 values were calculated with Eq. (3.3). Due
to additional effects, in particular B1 inhomogeneities and incomplete spoiling of
transverse magnetization, apparent T1 values as derived from Eq. [3.3] can deviate from
the real values, requiring several corrections [89]. In the presence of B1 inhomogeneities,
the nominal flip angle α deviates from the real flip angle.

The relative flip angle

distribution b1(x,y) is determined by the ratio of the effective flip angle αeff (x,y) (Eq.
[12]) and the nominal flip angle αnom:
b1 ( x, y ) =

α eff (x, y)
α nom

(3.16)

T1 values can be corrected by incorporating b1 information. The B1 map can be
used to correct the T1 values using the following equation [76]:
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T1 =

- TR
 Sα 1opt / sin(b1 ⋅ α1opt ) − Sα 2opt / sin(b1 ⋅ α 2 opt ) 
ln 

 Sα 1opt / tan(b1 ⋅ α1opt ) − Sα 2opt / tan(b1 ⋅ α 2opt ) 

(3.17)

Where Sα1opt and Sα2opt represent the acquired signal amplitude of the T1
measurement using the optimum flip angles.
Table 3-1: T1 values (ms) of DFA (2D and 3D FFE) with and without B1 correction and
IR-TSE

T1 from
TSE

Optimal
FAs

2D DFA
without
B1

2D DFA
with B1

3D DFA

3D DFA

1 Acq

1 Acq

without B1

with B1

144

[2°, 11.6°]

42

61

58

85

774

[2.5°, 14.2°]

58

84

336

482

1185

[3.1°, 17.5°]

65

96

449

662

1791

[7.1°, 39.4°]

54

80

680

1011

3586

[1.4°, 8.2°]

69

105

1268

1930

3.4 Results

Optimal flip angle set are [2°, 11.6°], [2.5°, 14.2°], [3.1°, 17.5°], [7.1°, 39.4°],
[1.4°, 8.2°] for T1 = 144, 774, 1185, 1791, 3586 ms with TR = 6.4 ms. Only the more
central sections of the 3D slab was selected to process the data analysis. Table 3-1
compared the 2D DFA and 3D DFA with and without B1 correction. The B1
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inhomogeneity is up to 20% according to the obtained B1 maps. The results of DFA,
MOLLI and LL studies compared with IR-TSE are shown in Table 3-2 and Figure 3-2.
The duration of MOLLI and LL data acquisitions ranged from 11 to 23s, adequate for a
breath hold.
The T1 results with 2D FFE did not vary across the samples as expected, and all
were much smaller compared to other methods, even after B1 correction. The 3D FFE
sequences were performed with two separate acquisitions using two optimal flip angles,
and two dynamic scans with two optimal flip angles in single acquisition. The T1
measurements from two separated acquisitions DFA method did not show close
agreement with the gold standard method (IR-TSE). However, the single acquisition 3D
DFA results showed good correlation with the gold standard method (IR-TSE). Also the
results with single acquisition DFA were comparable with MOLLI and better than the LL
method. Note that the accuracy of T1 measurements with 3D DFA was increased
significantly with B1 correction.
Table 3-2: T1 values (ms) of 3D FFE DFA (1 acquisition [Acq]and 2 acquisitions
[Acqs]) with and without B1 correction compared with IR-TSE, MOLLI and LL

T1 from
TSE

without B1

with B1

T1 from
LL

T1 from
MOLLI

T1 from
LLN

3D
DFA
1 Acq

3D
DFA
2 Acqs

3D
DFA
1 Acq

3D
DFA
2 Acqs

144

102

471

148

680

181

169

175

774

450

1322

678

1993

667

876

801

1185

643

1871

957

2785

863

1223

929

1791

1008

2951

1416

4146

1055

1551

1136

3586

1995

6648

2836

9464

1212

2210

1474
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Without B1 correction, the T1 values are significantly underestimated compared
with the gold standard. Also for the clinical interested T1 values (774 ms, 1185ms), the
results with B1 correction are about 34% and 33% smaller than results with B1
correction. After flip angle corrected, the T1 values are much closer to reference T1
values for each sample especially similar results for the T1 values shorter than 1000 ms.
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Figure 3-2: Comparison between T1 measurements with different techniques
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3.5 Discussion

In this study a fast 3D T1 mapping technique based on the DFA approach to
measure T1 values in a wide range was implemented and tested. The acquisition time was
about 1s per slice. A fast B1 mapping technique based on SDAM was employed to
correct the discrepancy of the actual flip angle from the nominal flip angle. The
consecutive applications of the B1 and T1 mapping sequences enable to generate the
comparable T1 measurement with MOLLI which is the most widely used myocardial T1
mapping sequence now. The described method is effective for a T1 range about 100-1200
ms, and thus the results showed that the single acquisition DFA with B1 correction is
promising to measure precontrast and postcontrast myocardial T1 values in the future.
However, the DFA with 2D gradient echo was not accurate and the error may be due to
the inappropriate excitation pulse shape. The outer slices of a 3D sequence are often
unusable since they fall at the edges of the excited slab where signal intensity and
contrast are sub-optimal [90]. Previous studies showed that highly accurate T1 maps were
produced only at the more central sections of the 3D slab [91, 92], therefore only the
central slice was employed to avoid the inaccurate T1 measurements at the outer edges o
the 3D slab.
With the VFA technique there is always a trade-off between high T1 accuracy
(using more flip angles) and high temporal resolution (using fewer flip angles) [76]. As
observed by Deoni et al [71], multiple averaging of T1 maps with dual flip angle
technique provides higher accuracy per unit scan time than single average, multiple flip
angle data. However, to apply this technique for cardiac purpose, a high temporal
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resolution is required. Therefore, two optimal flip angles without signal averaging were
chosen, which resulted in a temporal resolution about 1s per T1 map at a voxel size of 1×
1 ×6 mm3.
The accuracy of the described T1 mapping technique using the DFA approach
decreases continuously as T1 increases, which was also found in other 1.5 T and 3 T
studies [76]. However, for the clinical interested T1 range shorter than 1500 ms, the
agreement between the DFA and IR-TSE was good. According to Eq. (3.1), the acquired
gradient echo signal decreased with higher T1 values. For the very long T1 value, it is
important to maintain the highest possible SNR. Multiple signal averaging is one way to
increase SNR; however, it was not employed in this study because to minimize the
acquisition time. The SNR may also be improved by using a large slice thickness and
applying RF excitation pulses with a high specific bandwidth, which resulted in improved
slice excitation profiles.
The dominant source of error for T1 measurement using the VFA method is
spatial variations of the nominal FA [70]. The in plane variations arise from B1 field
inhomogeneities, which was up to 20% in this study. SDAM B1 mapping for cardiac
triggering sequence was performed to correct the measurements. We corrected B1 field
inhomogeneities by multiplying the optimal flip angles of the T1 measurement by the
relative flip angle distribution b1(x,y) derived from the B1 mapping measurement [76].
This assumption holds true only in the case of a linear relationship between the nominal
FA and the actual B1 amplitude of the RF pulse. For slice-selective pulses, however,
linearity represents only an approximation. The deviation from the linear relationship
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depends on the applied RF pulse shape. Also, image artifacts from imperfect spoiling and
steady state impair accurate T1 measurements.

3.6 Conclusion

In this study we corrected B1 field inhomogeneities to improve the T1
measurements with DFA by applying fast B1 mapping technique at 3 T. The results
showed that the single acquisition DFA with B1 correction produced significant
improvement in measuring a wide range of T1 values than without B1 correction at high
magnetic field strength. The T1 measurements with B1 correction are comparable with
the MOLLI and LL sequences. For the clinical interested myocardial T1 range, the DFA
with B1 calibration is in good agreement with the gold standard method (IR-TSE). The
acquisition time is about 1s per slice without cardiac ECG triggering applied. However,
this would result in a considerably longer acquisition time to trigger the ECG signal in
human study and further research is needed to optimize this method to realize clinical
application.
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CHAPTER IV
MYOCARDIAL T1 MAPPING TECHNIQUES: COMPARISON OF LOOK
LOCKER AND MOLLI SEQUENCES

4.1 Introduction

A variety of dedicated cardiac pulse sequences have been developed for T1
mapping, which can be applied to characterization of diseased myocardial tissue [39, 42,
44-50]. Among all the myocardial T1 mapping techniques, Look Locker (LL) was
proposed in 1970 [52] and has been widely used to identify the null inversion time (TI) of
myocardium for scar imaging, characterize myocardium without contrast agent injection
[31], measure the myocardial T1 in patients with cardiac amyloidosis [93], and with
ischemic heart [54], quantify the partition coefficient [53] and extracellular volume of
myocardium [94].
The modified Look Locker inversion recovery (MOLLI) sequence has gained
popularity [39, 45, 46, 48, 50] since it was developed from LL in 2004 [45]. This
sequence, which obtains images at the most quiescent state of the heart, contains several
important modifications from the original LL sequence, including electrocardiogram
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(ECG)-synchronized acquisition in a fixed window/phase of the cardiac cycle and
prolongation of the TI to fully reach longitudinal relaxation.
MOLLI is developed from LL, but has several significant modifications based on
LL: 1. setting the acquisition window in the fixed cardiac cycle; 2. prolonging the TI to
reach fully longitudinal relaxation. MOLLI and LL are more popular T1 mapping
techniques. MOLLI is being accepted as the reference to be compared with other new
techniques, such as Shortened MOLLI [50]. MOLLI should therefore be more reliable
than LL in determining T1 time, but the relationship between MOLLI results and those of
LL, particularly in patients with myocardial disease, has not yet been fully evaluated [95].
However, there is still unknown about the difference or agreement between these two
techniques in patients. Validation and comparison between techniques is still limited,
requiring further evaluation of the accuracy of these techniques pre- and post-contrast
agent injection in various patient groups. Furthermore, the accuracy of T1 mapping is
confounded by several factors, such as the types of T1 mapping acquisition sequence,
physiologic parameters, and presence of contrast material. Examining their advantages
and limitations are important to choose the more appropriate technique in certain
situation. Understanding the limitations of various T1 mapping techniques as applied in
cardiac imaging will help to ascertain true differences between patient groups resulting
from disease. However, differences in T1 values obtained either from different pulse
sequences or from different regions of the myocardium have not been well investigated.
MOLLI and LL techniques are more important clinical relevant T1 mapping
techniques. In this study, we therefore sought to compare precontrast and postcontrast T1
values obtained with these two techniques in phantom studies and in patient studies that
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included controls, patients with ischemic cardiomyopathy (ICM), and patients with
HCM. In vitro and in vivo T1 mapping studies were performed by LL and MOLLI to
evaluate the hypothesis that the accuracy of myocardial T1 measurements is dependent
on the diseased tissue characteristics, heart rate, T1 mapping methods and T1 value itself
which is different between before and after contrast agent injection. Static phantoms with
a wide range of T1 values were scanned to measure the T1 value using LL and MOLLI.
The sequences were applied to three groups of patients to be further compared the
estimation of T1 values pre- and post-contrast agent injection. Our goal is to establish a
protocol to accurately calculate myocardial T1 before and after injection of contrast agent
in clinical setting.

4.2 Materials and Methods

4.2.1 Phantom Studies

Liquid samples with varying concentrations of gadopentetate dimeglumine
(Magnevist; Schering, Berlin, Germany) doped with distilled water were prepared to
meet a T1 of 200 to 2000 ms. Phantoms were imaged on a 1.5 T scanner (Achieva XR;
Philips Medical Systems, Best, The Netherlands) with 3 T1 mapping techniques (IR-TSE,
MOLLI, and LL) using a simulated ECG to set the heart rate at 40, 60, 80, and 100 beats
per minute (bpm).
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4.2.2 Subjects Population

This study was approved by the local institutional review board. A review of
electronic health records identified eligible study subjects, including 5 patients (4 men, 1
woman; mean age ± SD, 44 ± 21 y) with normal left ventricular (LV) function, shape,
and size (all were evaluated for thoracic aorta disease); 5 patients (3 men, 2 women;
mean age ± SD, 63 ± 2 y) with ICM; and 16 patients (10 men, 6 women; mean age ± SD,
51 ± 15 y) with HCM. All patients provided written informed consent.

4.2.3 Imaging Procedure

Patients were scanned on a Philips 1.5 T scanner with a phased-array cardiac coil.
Four ECG leads were placed on the chest for synchronized image acquisition. For
delayed enhanced cardiac MRI, 0.2 mmol/kg of gadopentetate dimeglumine (Magnevist)
was administered at an injection rate of 2 mL/s (3 patients were injected with a single
dose because of impaired kidney function), followed by a 20- to 30-mL saline flush
through a 20-gauge cannula placed in an antecubital vein. For patients with HCM or
ICM, LL and MOLLI sequences were performed before and after (approximately 15
minutes) gadolinium administration at 2 short-axis levels (basal and mid cavity). For the
normal LV function (Normal LV) patients, the postcontrast time was shorter
(approximately 5 minutes) for clinical workflow.
LL sequences were performed with the following scan parameters: flip angle, 10°;
repetition time (TR), 7.7 ms; echo time (TE), 3.2 ms; measured pixel size, 1.9 ×1.7 mm;
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and slice thickness, 10 mm. After a 180° radiofrequency prepulse triggered by the R peak
of ECG, gradient-recalled echo images (number of images dependent on the patient’s
heart rate) were acquired throughout the cardiac cycle, with a phase interval of
approximately 80 ms between images. MOLLI sequences were performed at end-diastole
to minimize cardiac motion. Eleven MOLLI images were acquired from 3 successive IRprepared, ECG-triggered LL experiments (LL1, LL2, and LL3) with 3, 3, and 5 singleshot readouts, respectively. Each of the LL experiments started with a 180° prepulse; the
first single-shot readout was performed at inversion time (LL1 ≈ 130 ms, LL2 ≈ 267 ms,
and LL3 ≈ 350 ms) and at trigger delay time (400 ms) after the previous R-wave. The
scan parameters were as follows: flip angle, 35°; TR, 3.9 ms; TE, 1.95 ms; SENSE
reduction factor, 2; measured pixel size, 1.9 × 2.3 mm2; slice thickness, 10 mm; and
acquisition window, 191.1 ms.

4.2.4 Data Analysis

Myocardial T1 values were computed for every pixel with a 3-parameter
nonlinear curve fitting using a Levenberg-Marquardt algorithm: y = A – B exp (–t/T1*).
T1 was calculated from effective T1 (T1*) with the equation T1 = T1* ((B/A) – 1) [45].
Regional analyses were also performed to compare corresponding areas between MOLLI
and LL. Regions of interest (ROIs) were manually drawn in 1 image and then copied to
the remaining images to calculate T1 values. A total of 6 ROIs were drawn in the mid
myocardium (anteroseptal, septal, inferior, posterior, lateral, and anterior). The location
of a pixel position within the myocardium was described by its position relative to the
local wall thickness (relative distance to the endocardial and epicardial contour) and its
73

angular position relative to the wall. Care was taken to exclude epicardial structures and
the blood pool from myocardial ROIs. For patients with macroscopic scar, ROIs were
drawn to differentiate between scarred and remote areas. The area of all ROIs was
approximately 50 pixels, but each ROI area was dependent on the size of infarcted areas
in patients with delayed enhancement. The mean signal intensity of each ROI was used to
calculate T1 values. All image analyses were processed offline using Matlab (The
MathWorks; Natick, MA, USA).

4.2.5 Statistical Analysis

Statistical analysis was performed using SPSS 14.0 (SPSS, Inc, Chicago, IL).
Paired student t-tests and Bland-Altman analyses were used to compare T1 values
obtained with the MOLLI and LL techniques. A P value < 0.05 indicated statistical
significance.

4.3 Results

4.3.1 Phantom Studies

For the MOLLI and LL methods, there was a systematic underestimation of T1
times longer than 1000 ms; underestimation was more pronounced for higher heart rates
and longer T1 times (Table 4-1 and Figure 4-1). The duration of the breath-hold MOLLI
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and LL data acquisitions ranged from 14.7 s to 23 s. T1 values calculated with MOLLI
were shorter than those calculated with LL for T1 times shorter than 400 ms. The
techniques produced comparable results for T1 values between 400 ms and 500 ms. For
T1 times greater than 600 ms, values calculated with MOLLI were greater than those
calculated with LL. LL was associated with a higher percentage of error than MOLLI.
Table 4-1: T1 values in phantoms measured with MOLLI and LL versus IR-TSE at
simulated heart rates of 40 to 100 bpm

Heart Rate
(bpm)
40

60

80

100

Method

T1(ms)

IR-TSE

2655

1517

1094

854

760

448

251

194

LL

1855

1307

1028

862

783

504

428

300

MOLLI

2126

1442

1071

866

773

444

265

209

LL

1368

1131

932

844

770

526

444

319

MOLLI

1977

1361

1110

885

799

464

266

210

LL

1106

950

815

722

683

482

416

306

MOLLI

1652

1267

997

819

719

461

246

190

LL

903

858

731

655

629

467

399

306

MOLLI 1314 1099
946
785
710
467
245
182
bpm, beats per minute; IR-TSE, inversion recovery turbo spin echo; LL, Look-

Locker; MOLLI, modified Look-Locker inversion recovery.
Figures 4-2 and 4-3 show the dependence of T1 value on the simulated heart rates
obtained from LL and MOLLI, respectively. For both methods, the T1 values are not
dependent on heart rates when T1 values are shorter than 500 ms. This result agrees with
the previous studies that showed no significant difference was found between postcontrast T1 values at different heart rates [31, 46]. However, the T1 values decreases with
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Figure 4-1: Phantom studies. Percentage error in T1 estimations (LL and MOLLI)
At various simulated heart rates versus reference values (with IR-TSE). (In the
legend, L means LL, M means MOLLI, the numbers represent the heart rate)
increased heart rates when T1 values are longer than 600 ms, the dependence is more
significant for longer T1. This result agrees well with the previous study [31]. The
interested T1 value range is from 300-1200 ms in this study; therefore the dependence of
T1 on heart rate can not be neglected for the precontrast myocardium which is in the
range of 800-1200 ms.
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Figure 4-2: T1 estimation from LL at different simulated heart rates
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Figure 4-3: T1 estimation from MOLLI at different simulated heart rates
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Figure 4-4: Mean myocardial T1 values for each ROI using LL compared with MOLLI
for normal LV
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Figure 4-5: Bland-Altman analysis to express the intersequence agreement of the
precontrast myocardial T1 values using LL compared with MOLLI for normal LV. The
mean difference (bias) is represented by the black line and the 95% limits of agreement
limit are represented by the dashed lines.

4.3.2 In Vivo Studies

In patients with normal LV, precontrast T1 measurements calculated with MOLLI
were greater (983 ± 48 ms) than those calculated with LL (898 ± 69 ms; P < 0.001; t-test
for paired comparison) as shown in Figures 4-4 and 4-5. The postcontrast measurements
showed good agreement between LL (418 ± 44 ms) and MOLLI (420 ± 46 ms; P =
0.423) (Figures 4-4 and 4-6).
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Figure 4-6: Bland-Altman analysis to express the intersequence agreement of the
postcontrast myocardial T1 values using LL compared with MOLLI for normal LV
patients. The mean difference (bias) is represented by the black line and the 95% limits
of agreement limit are represented by the dashed lines.
In other patient groups, the precontrast myocardial T1 values obtained with
MOLLI (1031 ± 78 ms) were greater than those obtained with LL (910 ± 74 ms; P <
0.001). Specifically, the precontrast myocardial T1 values obtained with MOLLI were
greater than those obtained with LL for patients with ICM (1083 ± 136 ms vs 900 ± 112
ms; P < 0.001) and for patients with HCM (1029 ± 44 ms vs 917 ± 58 ms; P < 0.001)
(Figures 4-7,4-8 and 4-9). With MOLLI, the precontrast T1 values calculated for patients
with ICM (1083 ± 136 ms) and patients with HCM (1029 ± 44 ms) were greater than
values for the control patients (983 ± 48 ms). However, with LL, there was no significant
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difference among controls, patients with ICM, and those with HCM (898 ± 69 ms, 900 ±
112 ms, and 917 ± 58 ms, respectively).
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Figure 4-7: Scatterplot of myocardial T1 values obtained with LL and MOLLI
Although the paired t-test showed that post-contrast myocardial T1 values
obtained with MOLLI were significantly different from those obtained with LL, the mean
T1 values for MOLLI and LL were separated by less than 10 ms (474 ± 70 ms vs 465 ±
64 ms; P < 0.001). There was good agreement between LL (474 ± 85 ms) and MOLLI
(474 ± 93 ms) postcontrast T1 measurements for patients with ICM (P = 0.974); however,
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postcontrast values in patients with HCM were higher with MOLLI (488 ± 59 ms) than
with LL (474 ± 54 ms; P < 0.001).
For patients with HCM or ICM, MOLLI demonstrated much longer T1 values in
the infarcted area than did LL. In a representative patient with ICM, infarcted
myocardium showed very long precontrast T1 values but shorter postcontrast values
compared with values in remote myocardium (Table 4-2). For postcontrast images in the
remote area, LL demonstrated shorter T1 values than MOLLI; however, LL demonstrated
longer T1 values than MOLLI in the infarcted area.
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Figure 4-8: Bland-Altman analysis of myocardial precontrast T1 values obtained with LL
and MOLLI for all patients. The mean difference (bias) is represented by the black line
and the 95% limits of agreement limit are represented by the dashed lines.
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Figure 4-9: Bland-Altman analysis of myocardial postcontrast T1 values obtained with
LL and MOLLI for all patients. The mean difference (bias) is represented by the black
line and the 95% limits of agreement limit are represented by the dashed lines.

Figure 4-10:

Postcontrast MOLLI (left) and LL (right) images of a patient with ICM
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Table 4-2: T1 values in a patient with ICM measured with MOLLI and LL

T1(ms)
Precontrast

Basal

Middle

Postcontrast

Infarcted Area

Remote Area

Infarcted Area

Remote Area

LL

988

941

434

571

MOLLI

1151

995

418

600

LL

1076

929

393

572

MOLLI
1448
1047
369
578
ICM, ischemic cardiomyopathy; LL, Look Locker; MOLLI, modified Look

Locker inversion recovery.
There is different data acquisition process between LL and MOLLI. LL acquires a
series of T1-weighted images from different cardiac phases. MOLLI is based on LL with
the advantage of acquiring the images at the same phase within the cardiac cycle. In
addition, the longest inversion time can be set much longer with MOLLI than LL, which
is important to meet the requirement for the full recovery of longitudinal magnetization
(about 5*T1 of the sample to be measured). For T1 times around 1000 ms at 1.5T, two
cardiac cycles (about 2000 ms) would not be sufficient for magnetization to reach
equilibrium with LL; thus, it caused error in estimated T1 and this error is increased with
faster heart rate. Figure 4-11 showed the recovery curves of MOLLI and LL from a HCM
patient. For precontrast images, the recovery of MOLLI achieved equilibrium while the
recovery of LL was incomplete. For postcontrast images, the myocardial T1 time is about
500 ms and two cardiac cycles (about 2000 ms) enable almost full magnetization
recovery and accurate T1 quantification can be achieved with LL. The postcontrast
recovery curve of MOLLI lasted longer than the required time for fully relaxation;
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therefore, the last two data points were not necessary. The magnetization tipped down by
the radiofrequency pulse can recover to equilibrium state faster than the precontrast
myocardium. Figure 4-11 illustrates that the data points (TI ≥2000 ms) with very long
inversion time acquired with MOLLI were not necessary because the magnetization
reached equilibrium before 2000 ms.

4.4 Discussion

Our data demonstrate that the MOLLI sequence shows closer agreement to IRTSE than does LL over a wide range of T1 values in phantom studies. For myocardial T1
measurements, MOLLI and LL show close agreement in postcontrast values, but
precontrast T1 values obtained with MOLLI were longer than those obtained with LL.
The LL sequence, which acquires a series of T1-weighted images from different
cardiac phases, is widely used in clinical settings to identify the null TI of remote
myocardium for delayed enhanced imaging. This sequence has also been used to measure
myocardial T1 values in healthy volunteers [31] and various patient populations [37, 96].
MOLLI has an advantage over LL, as this sequence acquires images in a fixed phase of
the cardiac cycle. In addition, the TI can be much longer with MOLLI than with LL,
which allows for full recovery of longitudinal magnetization. With MOLLI, similar
contours of epicardial and endocardial myocardium can be drawn for each image, thus
facilitating automatic registration of corresponding areas of different images. The
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Figure 4-11:

Curves of precontrast (upper) and postcontrast (bottom) myocardial T1

recovery with MOLLI and LL from a patient with HCM (HR = 65 bpm)
86

acquisition window for MOLLI can be set for the most quiescent stage (end-diastole) of
the cardiac cycle, which reduces artifacts from cardiac motion.
Previous studies have demonstrated differences between MOLLI and LL for
precontrast and postcontrast images [95, 97]. In a recent study of MOLLI and LL
sequences used in imaging healthy volunteers [95], precontrast results showed that
myocardial T1 values with MOLLI were longer than those with LL, results similar to
those obtained in this study. Postcontrast results showed longer T1 values with LL than
with MOLLI [95]; however, our results showed good agreement between MOLLI and LL
sequences for postcontrast measurements in patients with normal LV. There are several
potential reasons for these differences. The longest TI for LL in the previous study [95]
was approximately 800 ms, whereas our longest TI for LL was approximately 1720 ms.
Postcontrast myocardial T1 values can range from 300 to 600 ms depending on the
timing of the postcontrast injection; for values longer than 300 ms, TI should be longer
than 1500 ms to allow for full recovery of longitudinal magnetization. A multiethnic
study of atherosclerosis showed good agreement between MOLLI and LL for
postcontrast myocardial T1 values after correction of MOLLI for postcontrast time [97].
In our study, the MOLLI and LL sequences agreed more closely for controls than
for patients with ICM or HCM. For precontrast measurements, the scarred myocardium
showed longer T1 values than remote areas, and the difference between values obtained
with MOLLI and LL was more significant. For postcontrast measurements, the scarred
myocardium showed shorter T1 values than remote regions; the T1 values obtained with
LL in scarred tissue were longer than those obtained with MOLLI.
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Several previous studies have demonstrated T1 changes in diseased myocardium.
In patients with chronic ischemic heart disease, T1 was found to be significantly shorter
in scarred tissue than in viable tissue 2 to 50 minutes after contrast with LL [54].
However, there was no obvious difference between scarred and viable myocardium in
precontrast T1 values obtained with LL, suggesting that normal and ischemic
myocardium cannot be differentiated based on precontrast T1 values with LL. However,
the precontrast T1 values in this study were much shorter than those found in other
studies that used MOLLI [45] and LL [53]; these studies reported precontrast T1 values
of approximately 1000 ms for normal myocardium. In another study, the precontrast T1
value in infarcted areas (1060 ± 61 ms) was higher than the T1 value in remote areas (987
± 34 ms) with MOLLI, but this difference in T1 was not enough to differentiate chronic
infarction areas from normal tissue [39]. Another study demonstrated a prolonged T1
value in patients with HCM (1208 ± 47 ms) at 3T compared with T1 in healthy controls
(1172 ± 45 ms) [98].
In our study, there was a consistent trend toward longer precontrast T1 values for
patients with ICM or HCM compared with controls. Precontrast T1 values obtained with
LL were not significantly different among the 3 groups, whereas with MOLLI, precontrast T1 values were elevated significantly in patients with ICM (1083 ± 136 ms) and
those with HCM (1029 ± 44 ms) versus controls (983 ± 48 ms). The reasons for this
increase in T1 values with MOLLI in patients with ICM or HCM are unclear. Complex
physical and biochemical changes during the pathological process could result in
differences between diseased heart muscle and normal myocardium in the local magnetic
field [99], leading to changes in local T1 values [100]. Increased myocardial T1 values in
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patients with HCM may be caused by the development of diffuse fibrosis with increased
collagen volume fraction. For patients with ICM, T1 elevation may be related to
contractile function impairment of the scarred myocardium; T1 values are increased in
hypokinetic and akinetic segments at 3T [101] .
Our study had several limitations. Several patients with HCM or ICM were
injected with a single dose of contrast agent because of impaired kidney function;
additionally, the postcontrast time for controls was shorter than for patients with HCM or
ICM. The postcontrast T1 values were therefore not completely comparable among these
groups. Only 2 short-axis slices were acquired with T1 mapping techniques, so some
slices with scar on delayed enhancement images may have been missed on T1 mapping
scans. Motion artifacts may have been more common in patients than in normal
volunteers, as patients may have had arrhythmia or may not have been able to hold their
breath as well as normal volunteers. In cases of infarcted heart, there was regional
myocardial wall remodeling, leading to differences in motion pattern across the whole
myocardium. Additionally, despite the advantages of the MOLLI sequence, the accuracy
of quantitative pixel-by-pixel T1 estimation is compromised by several limitations, such
as the single-shot acquisition method and the requirement for myocardial motion
registration among frames.

4.5 Conclusion
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In conclusion, the MOLLI sequence showed better agreement with the reference
T1 measurement technique (IR-TSE) than did the LL sequence in both phantom and
patient experiments. Although there were no obvious T1 changes between normal and
diseased myocardium with LL, precontrast T1 values with MOLLI showed a consistent
increase in patients with ICM or HCM compared with controls.
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CHAPTER V
VALIDATION AND QUANTIFICATION OF DIFFUSE MYOCARDIAL
FIBROSIS WITH T1 MAPPING AND LEFT VENTRICULAR BIOPSY

5.1 Introduction

Myocardial fibrosis has been shown to play an important role in the development
and progression of systolic and diastolic cardiac failure, and is frequently seen in all
forms of heart disease, including nonischemic, hypertensive, and diabetic heart disease
[102-105]. Regardless of the cause of cardiomyopathy, increasing myocardial fibrosis has
been shown to correlate with progressive deterioration of myocardial function [106-108].
Evaluating the extent of myocardial fibrosis may also help to predict progression to LV
dilation and dysfunction in patients with valvular heart disease, which may impact
decision making regarding when to send patients for surgery [109]. Furthermore, diffuse
fibrosis is treatable; noninvasively evaluating therapy management is desirable to follow
changes in the myocardium over time.
Although delayed contrast enhancement sequences on MRI are widely utilized for
assessing regional myocardial fibrosis/scarring due to ischemic heart disease [11], this
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relies on the relative difference in signal intensity between scarred and the presumed
normal adjacent myocardium to generate image contrast.

However, the collagen

deposition is mostly diffuse in nonischemic cardiomyopathy. DE MRI can not detect the
diffuse fibrosis because this technique relies on the difference in gadolinium washout
kinetics between the remote and abnormal myocardium. T1 mapping technique allows
the objectively showing the difference across normal and diseased tissues and has the
advantage over DE MRI by circumventing the need to null the relative normal
myocardium. ECV based on T1 mapping is a physiological parameter showing the extent
of diffuse fibrosis intuitively.
Prior human studies have evaluated alterations in T1 relaxation due to fibrosis
with T1 mapping methods [3, 42, 46, 48, 109]. Null point on DE MRI which is related
with postcontrast T1 value was used as index of diffuse fibrosis [110]. This index showed
shorter value in dilated cardiomyopathy and hypertrophic cardiomyopahty than controls.
Iles et al [3] employed the postcontrast myocardial T1 time obtained with VAST
sequence as an index of diffuse fibrosis. Postcontrast myocardial T1 times were shorter in
nine heart failure patients than controls and correlated histologically collagen content on
right ventricular endomyocardial biopsy.

However, global T1 times were correlated to

only right ventricular endomyocardial biopsy in nine special patients who had undergone
heart transplant. Global postcontrast T1 values with LL were also inversely correlated
with endomyocardial biopsy from right ventricle in patients with cardiomyopathy [111].
Both studies did not correlate the sites where the tissue samples were taken with the
exactly regional T1 values. They may make an assumption that the diffuse myocardial
fibrosis is homogenous across the myocardium and the globe T1 value can represent the
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regional T1 value, while this assumption has not been validated which gave some
uncertainty to this study. Iles et al [3] used VAST which is a 2D fast gradient echo
sequence with variable sampling of k-space after inversion recovery prepared, which has
not been well validated in the literature. Therefore, it is still unclear if the correlation
found in this small group of patients represents a true histological correlation. Flett et al
[29] validated equilibrium contrast CMRI (EQ–CMRI) to quantify diffuse myocardial
fibrosis against the current gold standard of surgical myocardial biopsy collagen volume
fraction (CVF) quantification in patients with aortic stenosis and hypertrophic
cardiomyopathy. The calculated myocardial contrast volume of distribution (Vd (m))
correlated with biopsy histological analysis. However, these data are preliminary and
have to be confirmed in larger and different cardiomyopathy populations. Furthermore,
this method imposes a more complex image acquisition protocol that questions its
applicability in the routine clinical workflow.
The purpose of this study is to validate the use of high-resolution T1 mapping
with MOLLI to quantify extracellular volume (ECV) in areas of diffuse fibrosis against
human operative myocardial biopsy in patients with HCM.

5.2 Materials and Methods

5.2.1 Patient Population
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18 patients with hypertrophic cardiomyopathy were recruited. Height, weight,
creatinine, glomerular filtration rate (GFR), heart rate, and contrast dose were recorded.
The study was approved by the local ethics committee, and all subjects gave written
informed consent.

5.2.2 Imaging Procedure

Subjects underwent MRI examinations using 1.5 T Achieva MR Systems (Philips
Medical Systems, The Netherlands) with a prototype 32-channel coil (Invivo, USA) with
a phased-array cardiac coil. MOLLI sequences were performed at end-diastole (ED) to
minimize the cardiac motion, during the cardiac cycle at 2-3 short-axis levels (basal,
middle and apical cavity). Data acquisition consists of a single-slice, single-shot,
balanced fast-field echo (bFFE ) pulse sequence combined with SENSE with a reduction
factor of 2, number of lines of k-space (TFE factor) = 49, dummy acquisitions =13,
partial Fourier acquisition, flip angle = 35°, repetition time (TR) = 3.9 ms, echo time
(TE) = 1.95 ms, field of view (FOV) = 380 ×342 mm2, matrix = 240 ×151, measured
pixel size = 1.9 ×2.3 mm2, slice thickness = 10 mm, and acquisition window = 191.1 ms.
The MOLLI sequences were performed within in one breath hold (approximately 11
seconds depending on patients’ heart rate).
For delayed enhanced CMRI, gadopentetate dimeglumine (Magnevist; Schering,
Berlin, Germany) was administered at a dose of 0.15 mmol per kilogram of body weight
at an injection rate of 2 mL/s, followed by a 20- to 30-mL saline flush through a 20-gauge
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cannula placed in an antecubital vein. MOLLI pulse sequences were performed before
and about (15 – 20 minutes) after gadolinium administration.

5.2.3 Histology

Blood specimens were acquired when the IV is placed for the MRI study. The
specimens will be stored in the Prevention Research Laboratory. Hematocrit of each
patient was determined from blood specimen in Cleveland Clinic Main Laboratory.
At the time of open heart surgery, the surgeon took myectomy biopsy from distal
anterior wall. The tissue samples were fixed immediately in 10% buffered formalin,
embedded in paraffin, routinely processed, and stained with picrosirius red and Mason
trichrome to differentiate between myocardium and fibrotic areas. The tissue specimens
were cut into 8 µm thick sections using a microtome. Slides were imaged at high
magnification (x40) using the Aperio ScanScope digital scanner and visualized using
VisionScope V10 (Aperio Technologies). A positive pixel count algorithm was applied to
analyze the area and intensity of a given stain. A color deconvolution algorithm was
applied to separate the image into two or three channels each corresponding to a different
color in order to allow accurate measurement of the area and intensity of each color
individually even where stains were superimposed. Collagen was quantified as the
percentage of total endomyocardial area using Aperio software by a cardiologist. For
each patient, the number of slides was different. Histology analysis was performed by Dr.
Patrick Collier and then presented to the author of this dissertation.
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5.2.4 Image Analysis

Regional T1 values and global T1 values from the entire myocardium, blood T1
values were obtained using cvi42 (Circle Cardiovascular Imaging Inc., Calgary, AB,
Canada) to obtain the mean T1 value using curve fitting. T1 values were further
processed to calculate extracellular volume fraction (ECV) using the following equations
[112]. The concentration of contrast agent (CA) is directly related to the difference
between the difference between precontrast and postcontrast reciprocal values of T1
(∆R1):

 1 
 1 
∆R1 = γCCA =   −  
 T 1  post  T 1  pret

(5.1)

Where γ is defined as the relaxivity of the contrast agent.
The partition coefficient for contrast agent in myocardium and blood is defined
as:

λ=

∆R1myocardium

(5.2)

∆R1blood

Assuming steady state between myocardium and blood, ECV and ∆R1 are related
as follows:
ECVmyocardium
∆R1myocardium

=

ECVblood
∆R1blood

(5.3)

The ECV of blood can be quantified as follows:
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ECVblood = 1 − hematocrit

(5.4)

Therefore, myocardial ECV can be calculated as follows:
ECVmyocardium =


1
1
ECVblood × 
−
 T1
 myocardium , post T 1myocardium , pret

 
1
1
 /
−
  T1
  blood , post T 1blood , pret






(5.5)

5.2.5 Statistical Analysis

All CMR data and histological images were analyzed in a blinded fashion. The
correlation between the two classes of analysis was assessed using Pearson’s test. P<0.05
was considered statistical significant. Statistical analysis was performed using SPSS
version 14 (SPSS, Inc, Chicago, IL).

5.3 Results

5.3.1 Histological Biopsy Evaluation

The histological collagen volume fraction was from 0.3% to 36.9% in patients
with HCM. Table 5-1 showed collagen volume fraction (CVF) quantified using Aperio
software from a cardiologist. Figure 5-1 showed three representative slides with minimal,
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moderate and more extensive interstitial fibrosis from left to right. Sections with collagen
are yellow and myocytes appearing red.
Table 5-1: Histological analyses compared with ECV from T1 measurements

ECV from
CVF from
Patient

Basal

Basal

Middle

Middle

Anteroseptal

Global

Anteroseptal

Global

Hematocrit
Aperio

1

3.0%

31.9

25.6%

27.1%

25.6%

31.7%

2

0.5%

37.3

23.0%

26.3%

23.0%

24.5%

3

2.8%

36.0

35.3%

33.7%

27.1%

26.4%

4

3.7%

36.6

23.8%

25.9%

25.5%

27.0%

5

4.0%

37.7

42.3%

29.8%

24.8%

26.5%

6

3.5%

46.5

24.4%

24.0%

20.0%

21.2%

7

3.0%

44.6

N/A

N/A

27.4%

28.6%

8

8.1%

46.6

20.0%

25.6%

25.6%

24.9%

9

3.9%

37.6

N/A

N/A

24.3%

22.9%

10

4.2%

42.5

26.1%

25.4%

25.5%

26.8%

11

0.3%

44.3

N/A

N/A

20.7%

21.3%

12

1.4%

43.7

25.6%

28.1%

27.5%

27.0%

13

1.8%

40.8

26.8%

26.1%

22.1%

22.8%

14

0.5%

43.7

31.6%

25.2%

25.1%

23.2%

15

3.7%

38.0

24.6%

26.2%

26.8%

28.0%

16

36.9%

38.7

40.7%

40.9%

41.9%

41.3%

17

6.5%

38.9

31.6%

30.2%

32.2%

32.5%

18

7.7%

42.2

34.5%

34.1%

34.8%

34.2%
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Figure 5-1: Histological images (images provided by Dr. Patrick Collier)

5.3.2 Noninvasive In Vivo MRI Measurement of Fibrosis

In this validation study, fibrosis was quantified in the anteroseptal wall of basal
and middle, also global mean T1 value of the basal and middle slice. The basal
anteroseptal area is missed in three patients because of the cardiac motion during the
image acquisation. ECV was calculated based on the precontrast and postcontrast blood
and myocardial T1 values. Four sets of ECV representing results from regional and
global analyses of basal and middle slices were correlated with histological results.
Figure 5-2 shows the best correlation obtained with anteroseptal region of middle slice.
The coefficients are shown in Table 5-2.
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Figure 5-2: Relationship of ECV on MRI and collagen volume fraction of histological
analysis

Table 5-2: Statistical correlation of histological analyses and CMRI

Analysis

R
Pearson
Square Coefficient

P Value

Regional Basal

0.23

0.36

<0.001

Global Basal

0.61

0.40

<0.001

Regional Middle

0.67

0.52

<0.001

Global Middle

0.60

0.48

<0.001
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5.4 Discussion

Our results provide histological validation for the use of ECV based on T1
mapping to noninvasively assess interstitial myocardial fibrosis in patients with
hypertrophic cardiomyopathy. Higher ECV was associated with a greater degree of
histologically defined interstitial fibrosis. Our current results are in agreement with
previous findings related with ECV measurements with or without histology validation.
ECV calculated for normal volunteers with LL incorporating a pharmacokinetic
model shows a range of 18.8%-38.0% [31]. Schelbert et al [66] calculated ECV in normal
volunteer with MOLLI were in the range of 19.3%-29.2% and 18.4%-29.1% using
contrast agent injection with infusion and bolus, respectively. ECV calculation with
MOLLI was also performed in patients with myocardial infarction and nonischemic
cardiopathy [94]. ECV was 51 ± 8% in patients with myocardial infarction which was
much higher than the atypical late enhancement areas in nonischemic cardiomyopathy
(37 ± 6%) and “normal appearing” myocardium (36 ± 3%). In only one study at 3 T, the
mean ECV values calculated with MOLLI are 26.7 ± 1.0% for normal human subjects,
which agrees well with the ECV values in normal volunteers at 1.5 T. Therefore, the
normal ECV appears to approximately 25% or less. Our ECV calculated with MOLLI in
patients with hypertrophic cardiomyopathy are from 20.0% - 42.3% (27.8% ± 5.4%),
which means the diffuse fibrosis is not severe in most of the patients.
There has been limited previous quantitative validation of ECV based on T1
measurement methods with histopathologically demonstrated fibrosis in myectomy
specimen. In only one previous report, ECV values from 18 patients with aortic stenosis
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(R2 = 0.86, Kendall Tau coefficient = 0.71) and 8 hypertrophic cardiomyopathy (R2=
0.62, Kendall Tau coefficient = 0.52) were correlated with biopsies from LV [29].
However, the T1 mapping method in this study was not widely used in a diverse
population with cardiomyopathy, and the EQ-CMR technique is complex and therefore is
not easily to be added in clinical workflow. Our correlation ((R2= 0.67, Pearson
coefficient = 0.52) is comparable with this previous study although the correlation for
patients with HCM in both our study and study of Flett et al [29] is not as strong as for
patients with aortic stenosis, this may be due to the less diffuse nature of the fibrosis in
hypertrophic cardiomyopathy [29]. We noticed the histological CVF in Flett et al [29]
study were 6% to 39.38% in patients with aortic stenosis and 10.4%-30.6% in patients
with hypertrophic cardiomyopathy, and were 0.3%-36.9% in our study. The histological
CVF is generally lower than the ECV calculated from T1 values, which may be due to
two reasons: 1) the CVF is quantified after fixation process; 2) ECV may include other
extracellur matrix expansion beside collagen. In our study, the correlation of regional
ECV from middle slice is better than basal slice. This may be due to the more motion at
the basal slice than middle slice, and the blood ejected out from LV out tract causing
artifacts on the T1 weighted images. Even the best correlation we saw in this study is not
strong. Firstly, this is thought to be related with less diffuse nature of fibrosis in patients
with HCM. Secondly, sample size of biopsy may be too small and three patients only
have 1 slide although there are up to 3 slides for other patients. Thirdly, the precontrast
blood T1 value is very long and has big standard deviation which can cause error for the
ECV calculation. Finally, the image quality is impaired for patients not breath-holding
well, with larger size and arrhythmia.
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Although our study improved the understandings about the future clinical
application of T1 mapping and ECV, there are still several limitations. Firstly, the T1
values were affected by several factors, such as changing heart rate of patients, cardiac
motions causing the need for co-registration of images. Secondly, the range of ECV for
patients and normal volunteers overlapped making it difficult to find the right cutoff
value to differentiate the normal and diseased tissue. ECV calculation only correcting
blood fraction with hematocrit, however, there are patients’ specific factors (eg,
glomerular filtration rates, gadolinium dose, postcontrast time) were not correct. Also the
ECV of normal volunteers calculated based on T1 measurements with LL showed a wide
range from 18.8% to 38.0% [31], which gives difficulty in cutting the edge of diseased
and normal myocardium. Finally, the number of patients recruited is not big enough;
more patients are needed to avoid the bias.

5.5 Conclusion

In conclusion, noninvasive assessment of myocardial ECV correlates moderately
with interstitial fibrosis as assessed by means of invasive biopsy in patients with
hypertrophic cardiomyopathy in our study. Further investigation is required to determine
whether this measure can effectively guide clinical intervention and improve morbidity
and mortality of patients with heart failure. Although more work needs to be done on the
robustness of the technique, this technique shows promise in the quantitative evaluation
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of diffuse myocardial fibrosis, and hence may have potential applications with DE MRI
in heart failure, cardiomyopathy, and valvular heart disease.
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CHAPTER VI
CONCLUSION AND FUTURE RESEARCH

6.1 Conclusion

Clinical validation of MRI sequences is the final and also the most important
point to realize the application of the sequences in clinical application. Therefore, while
T1 mapping is a promising tool to assess myocardial fibrosis when combined with DE
MRI, further validation is necessary to realize the clinical application in the context of
myocardial assessment in patient with suspected cardiomyopathy.
In the current thesis project, we evaluated several aspects of T1 mapping methods
which were incompletely understood. Firstly, variation of myocardial T1 at 1.5 T was
assessed at three time points within the cardiac cycle in healthy volunteers and patients
without myocardial disease. Our results showed that although the variation is statistically
significant among the different time points, the variation is less than 39 ms which is
within the standard deviation of the myocardial T1 mapping technique. Therefore, we
feel that this difference can not be considered clinically significant.
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Secondly, a quantitative evaluation of T1 measurement with DFA based on 3D
FFE with B1 correction was established and compared with gold standard method. The
accuracy of T1 measurement was increased with incorporating B1 information, which
supported the errorrous T1 measurements without B1 correction in the study showing
severe drop of myocardial T1 value from ES to ED.
Thirdly, the two different myocardial T1 mapping techniques were compared in 3
patient groups precontrast and postcontrast to examine the difference and agreement
between the techniques. These results gave guidance to interpret the clinical finding when
comparing the interstudy results with MOLLI or LL.
Finally, the T1 mapping technique was applied in a group of patients with diffuse
myocardial fibrosis eligible for myectomy surgery. Precontrast and postcontrast
myocardial and blood T1 values were assessed to identify and quantify myocardial
fibrosis, with subsequent histological validation based on LV biopsies. Our results
showed positive correlation of histolocial fibrosis with ECV calculated from T1 mapping
technique. Although the correlation coefficient is not strong, it showed the trend between
the noninvasive and invasive methods. Larger group of patients and in multicenter
settings clinical studies are needed to realize its clinical applications.

6.2 Future Research

6.2.1 3D DFA with B1 Correction in Human Studies
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Optimization the method to ensure effective gradient spoiling and a steady state
condition needs to be developed to meet the limitation of the acquisition time by
increasing the duration of the crusher gradients (increased dephasing of transverse spin
components) and applying a sufficient number of dummy excitations. Using cardiac
triggering to acquire T1-weighted images at defined cardiac cycle in human subjects is
necessary to realize the clinical application of DFA method.

6.2.2 Motion Registration of T1 Mapping Technique

Patient movement can result in the slices being substantially different in
appearance although the same slice was selected, such as the anterosepatl region missing
often at basal slice. Automatic motion registration to post processing T1-weighted images
should be employed to improve the accuracy of T1 measurement and therefore ECV
calculation.

6.2.3 Correct the Factors Affecting ECV Calculation

Besides the hematocrit, there are also several factors may affect the accuracy of
ECV calculation, such as contrast agent dose, glomerular filtration rate, postcontrast
injection time. It is necessary to incorporating these factors to further optimize this
method. Further investigation is required to determine whether this measure can
effectively guide clinical intervention and improve morbidity and mortality of patients
with heart failure.
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6.2.4 ECV Applications in 3 T and Cardiomyopathies

ECV can be applied to 3 T studies to evaluate whether it will be more sensitive
than 1.5 T. Although more work needs to be done on the robustness of the technique, this
technique may have potentially wide applications in heart failure, cardiomyopathy, and
valvular heart disease to follow the changes of myocardium noninvasively. Longitudinal
imaging of such changes could be applied to individualization of therapy by assessing
treatment response in a given patient, and to the evaluation of prospective therapies for
heart failure.
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